Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 13060. Отображено 100.
19-01-2012 дата публикации

Compounds for the prevention and treatment of cardiovascular diseases

Номер: US20120015905A1
Автор: Henrik C. Hansen
Принадлежит: Resverlogix Corp

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

Подробнее
02-02-2012 дата публикации

Bicyclic mglur5 positive allosteric modulators and methods of making and using same

Номер: US20120028955A1

In one aspect, the invention relates to bicyclic mGluR5 positive allosteric modulators, for example 6-(phenylethynyl)-3,4-dihydroisoquinolin-1(2H)-one, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Подробнее
09-02-2012 дата публикации

Modulators of Cellular Adhesion

Номер: US20120035154A1
Принадлежит: Sarcode Bioscience Inc

The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R 1 -R 4 , n, p, A, B, D, E, L and AR 1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).

Подробнее
23-02-2012 дата публикации

Diacylethylenediamine compound

Номер: US20120046292A1
Принадлежит: Astellas Pharma Inc

[Problem] A compound which is useful as an anti-obesity agent is provided. [Means for Solution] The present inventors have investigated a compound having a DGAT1 inhibitory action, which is promising as an active ingredient of a pharmaceutical composition for treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases, and as a result, they have found that the diacylethylenediamine compound of the present invention has an excellent DGAT1 inhibitory action, thereby completing the present invention. That is, the diacylethylenediamine compound of the present invention has a DGAT1 inhibitory action, and can be therefore used as an agent for preventing and/or treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases.

Подробнее
22-03-2012 дата публикации

Estrogen receptor modulators and uses thereof

Номер: US20120071535A1
Принадлежит: Aragon Pharmaceuticals Inc

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Подробнее
12-04-2012 дата публикации

Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same

Номер: US20120088746A1
Принадлежит: PFIZER INC

Compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

Подробнее
12-07-2012 дата публикации

Rho kinase inhibitors

Номер: US20120178752A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R 1 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Подробнее
12-07-2012 дата публикации

Cyanoisoquinoline compounds and methods of use thereof

Номер: US20120178755A1
Принадлежит: Fibrogen Inc

The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:

Подробнее
26-07-2012 дата публикации

Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor

Номер: US20120190845A1

The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X 1 -X 5 , R 5 -R 8b , Z 1 -Z 2 and Ar 1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.

Подробнее
09-08-2012 дата публикации

Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp)

Номер: US20120202795A1
Принадлежит: Aventis Pharmaceuticals Inc

The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R 1 , R 2 , R 3 and R 4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5′-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

Подробнее
09-08-2012 дата публикации

Dual small molecule inhibitors of cancer and angiogenesis

Номер: US20120202800A1
Автор: Milton L. Brown

The present invention provides analogs and derivatives of thalidomide which inhibit cancer and angiogenesis. The present invention further provides compounds which disrupt microtubule polymerization. The present further provides methods of treating cancers comprising mutant p53.

Подробнее
23-08-2012 дата публикации

Viral polymerase inhibitors

Номер: US20120214783A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Compounds of formula I: wherein X, R 2 , R 3 , R 3a , R 3b , R 5 and R 6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.

Подробнее
23-08-2012 дата публикации

New compounds, pharmaceutical compositions and uses thereof

Номер: US20120214785A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Подробнее
13-09-2012 дата публикации

Compositions and Methods for Treatment of Eye Disorders

Номер: US20120232019A1
Принадлежит: Sarcode Bioscience Inc

The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

Подробнее
15-11-2012 дата публикации

Novel compounds with high therapeutic index

Номер: US20120289471A1
Автор: V. Ravi Chandran
Принадлежит: Signature R&D Holdings LLC

The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced pharmacological and pharmaceutical properties. In fact, the novel drug derivatives of the present invention enhance at least one therapeutic quality, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

Подробнее
13-12-2012 дата публикации

Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex

Номер: US20120316066A1
Принадлежит: Intrexon Corp

The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.

Подробнее
20-12-2012 дата публикации

Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof

Номер: US20120322785A1
Принадлежит: Genentech Inc

The invention provides novel compounds having the general formula: wherein X 1 is N or N + O − , and one of X 2 , X 3 and X 4 is N or N + —O − and the remainder of X 2 , X 3 and X 4 is C. R 2 , R 3 , R 4 , R 5 , R 6 . A, B and Y are as described herein. Additionally compositions compounds of Formula I and methods of use are further described herein.

Подробнее
03-01-2013 дата публикации

Cyclic amine bace-1 inhibitors having a benzamide substituent

Номер: US20130004518A1
Принадлежит: Merck Sharp and Dohme LLC

Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is R is —C(O)—N(R 27 )(R 28 ) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

Подробнее
14-02-2013 дата публикации

Process for producing cisatracurium and associated intermediates

Номер: US20130041154A1
Принадлежит: Chemagis Ltd

The present invention provides a process of producing cisatracurium compounds, e.g., cisatracurium besylate, from isoquinolinium salts of the structural formula (VIIA) wherein X − is an anion and R is H or a C 1 -C 6 alkyl, or an activated form of the carboxylic acid with 1,5-pentanediol to form a cisatracurium salt, optionally via an intermediate compound (VIII). The cisatracurium compounds can be purified using simple techniques to afford pure cisatracurium besylate without the need for HPLC purification.

Подробнее
18-04-2013 дата публикации

USE OF ISOQUINOLONES FOR PREPARING DRUGS, NOVEL ISOQUINOLONES AND METHOD FOR SYNTHESISING SAME

Номер: US20130096083A1
Принадлежит:

The use of isoquinolones for preparing drugs, including novel isoquinolones as well as their synthesis method. In particular, isoquinolone derivatives used in the treatment of pathological angiogenesis, and more particularly of cancer. 136-. (canceled)38) A method for the prevention and treatment of mammals claim 37 , in particular humans claim 37 , suffering from pathological angiogenesis claim 37 , in particular retinopathies claim 37 , or benign or malignant (cancerous) tumours claim 37 , comprising administering to a mammal in need thereof an effective amount of at least one compound of general formula (I) according to .39) A method for the prevention and treatment of mammals claim 37 , in particular humans claim 37 , suffering from pathological angiogenesis claim 37 , in particular retinopathies claim 37 , or benign or malignant (cancerous) tumours claim 37 , comprising administering to a mammal in need thereof an effective amount of at least one compound of general formula (I) according to claim 37 , as a protein phosphatase 1 inhibitor claim 37 , vascular-disrupting agent and antiproliferative agent.40) A method for the prevention and treatment of mammals claim 37 , in particular humans claim 37 , suffering from pathological angiogenesis claim 37 , in particular retinopathies claim 37 , or benign or malignant (cancerous) tumours claim 37 , comprising administering to a mammal in need thereof an effective amount of at least one compound of general formula (I) according to claim 37 , as a tubulin polymerization inhibitor claim 37 , vascular-disrupting agent and antiproliferative agent.41) A method for the prevention and treatment of mammals claim 37 , in particular humans claim 37 , suffering from pathological angiogenesis claim 37 , in particular retinopathies claim 37 , or benign or malignant (cancerous) tumours claim 37 , comprising administering to a mammal in need thereof an effective amount of at least one compound of general formula (I) according to ...

Подробнее
18-04-2013 дата публикации

Isoquinolin-3-Ylurea Derivatives

Номер: US20130096119A1
Принадлежит:

The invention relates to isoquinolin-3-ylurea derivatives of formula (I) wherein Rrepresents (C-C)alkyl, (C-C)haloalkyl or cyclopropyl, Rrepresents H and the substituents Rand Rand Rhave the meanings disclosed in the specification; and to the salts of such compounds. These compounds are useful for the prevention or the treatment of bacterial infections. 4. The compound according to claim 1 , wherein Rrepresents (C-C)alkyl; or a salt thereof.5. The compound according to claim 1 , wherein Rrepresents ethyl; or a salt thereof.6. The compound according to claim 1 , wherein Rrepresents H; or a salt thereof.7. The compound according to claim 1 , wherein Rrepresents methyl; or a salt thereof.8. The compound according to claim 1 , wherein:{'sup': 3', '12', '14', '13', '12', '13', '14, 'sub': 1', '2', '1', '2', '1', '2', '1', '2', '1', '2', '1', '2, 'Rrepresents a group (B1) wherein either each of Band Brepresents H and Brepresents OH, halogen, acetyl, acetylamino, acetylaminomethyl, aminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, (C-C)alkylsulfonyl, (C-C)alkoxy, (C-C)alkoxycarbonyl, cyano, amino-(C-C)alkyl or hydroxy-(C-C)alkyl, or each of Band Brepresents H and Brepresents acetyl, acetylamino, acetylaminomethyl, aminocarbonyl, dimethylaminocarbonyl, aminosulfonyl, (C-C)alkylsulfonyl, cyanomethyl or hydroxymethyl;'}{'sup': '3', 'sub': '2', 'Rrepresents a group (B2) wherein X represents CH;'}{'sup': '3', 'Rrepresents a group (B3);'}{'sup': '3', 'Rrepresents a group (B4);'}{'sup': '3', 'Rrepresents a group (B6); or'}{'sup': '3', 'Rrepresents quinolin-3-yl, imidazo[1,2-a]pyridin-6-yl, (thiazol-5-yl)carbonylamino, pyridin-3-ylcarbonylamino or pyridin-4-ylcarbonylamino;'}or a salt thereof.9. The compound according to claim 1 , wherein Rrepresents H; or a salt thereof.10. The compound according to claim 1 , wherein Rrepresents methyl; or a salt thereof.11. The compound according to claim 1 , wherein:{'sup': '2', 'Rrepresents halogen;'}{'sup': '2', 'Rrepresents a group (A1 ...

Подробнее
18-04-2013 дата публикации

ISOQUINOLINE DERIVATIVE

Номер: US20130096310A1
Принадлежит: TAISHO PHARMACEUTICAL CO., LTD.

A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a pharmaceutical. 2. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R claim 1 , R claim 1 , Rand Reach independently represent a hydrogen atom claim 1 , a halogen atom claim 1 , a Calkyl group claim 1 , or a Calkoxy group (except the compound or a pharmaceutically acceptable salt thereof in which both Rand Rare hydrogen atoms and both Rand Rare Calkoxy groups).3. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein{'sup': h', 'i', 'h, 'sub': '1-6', 'X is the formula: —CRR—, wherein Ris a hydrogen atom, a Calkyl group, or a halogen atom;'}{'sup': 'i', 'sub': '1-6', 'and Ris a Calkyl group, or a halogen atom.'}4. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein{'sub': 1-6', '1-6', '1-6, 'Z is a benzene ring substituted with a Calkyl group, a halogen atom, a Calkoxy group, or a Chaloalkyl group.'}5. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein{'sup': '1', 'Ris a phenyl group, which may be substituted with a halogen atom;'}{'sup': '3', 'Y is the formula: —CONR—W—;'}{'sub': '1-6', 'W is a Calkylene group;'}{'sup': 'a', 'Ris a carboxy group;'}{'sup': b', 'c, 'Rand Rare each a hydrogen atom, and'}{'sup': d', 'e', 'f', 'g, 'R, R, Rand Rare each a hydrogen atom.'}6. A preventive or a remedy for asthma claim 1 , atopic dermatitis and allergic rhinitis claim 1 , comprising the compound or a pharmaceutically acceptable salt thereof according to as an active ingredient. The present invention relates to a compound having an inhibitory effect on CRTH2 (Chemoattractant Receptor-homologous molecule expressed on Th2 cells), and pharmaceutical preparations containing the compound as an active ingredient.CRTH2 is a G-protein coupled 7th transmembrane domain molecule cloned by ...

Подробнее
02-05-2013 дата публикации

1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS

Номер: US20130109685A1
Принадлежит: ACTELION PHARMACEUTICALS LTD.

The present invention relates to 1-phenyl-substituted heterocyclyl derivatives of the formula (I), 2. The compound according to claim 1 , whereinX represents —O— or a bond;Y represents methandiyl;Z represents O;n represents 0 or 1;{'sup': '1', 'claim-text': [{'sub': 1', '2', '1', '2, '(C-C)alkyl which is mono-substituted with optionally substituted aryl, optionally substituted heteroaryl or optionally substituted aryl-(C-C)alkoxy; or'}, 'cyclopropyl which is mono-substituted with optionally substituted aryl;, 'Rrepresents'}{'sup': '2', 'Rrepresents hydrogen, trifluoromethyl or fluoro;'}{'sup': '3', 'Rrepresents hydrogen or fluoro;'}{'sup': '4', 'Rrepresents hydrogen;'}{'sup': '5', 'Rrepresents halogen or cyano;'}{'sup': '6', 'Rrepresents hydrogen;'}{'sup': '7', 'Rrepresents hydrogen; and'}{'sup': '10', 'Rrepresents —C(O)OH;'}or a salt thereof.3. The compound according to claim 1 , whereinX represents —O—;or a salt thereof.4. The compound according to claim 1 , whereinX represents a bond;or a salt thereof.5. The compound according to claim 1 , whereinZ represents O;or a salt thereof.6. The compound according to claim 1 ,wherein{'sup': '1', 'claim-text': [{'sub': 1', '4', '3', '6', '1', '2', '1', '2, '(C-C)alkyl which is mono-substituted with (C-C)cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted aryl-(C-C)alkoxy or optionally substituted heteroaryl-(C-C)alkoxy; or'}, {'sub': 1', '4, 'cyclopropyl which is mono- or di-substituted with (C-C)alkyl, mono-substituted with optionally substituted aryl or mono-substituted with optionally substituted heteroaryl;'}], 'Rrepresents'}or a salt thereof.7. The compound according to claim 1 , wherein{'sup': '2', 'sub': 1', '4', '1', '4', '1', '4, 'Rrepresents hydrogen, (C-C)alkyl, (C-C)alkoxy, (C-C)fluoroalkyl or halogen;'}or a salt thereof.8. The compound according to claim 1 , ...

Подробнее
02-05-2013 дата публикации

Chemical Compounds

Номер: US20130109708A1
Принадлежит: Pfizer Ltd

The invention relates to sulfonamide derivatives, to their use in medicine, to 5 compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I):10 X NH O S O O R1 R2 R5 R4 R3 Het1 (I) or a pharmaceutically acceptable salt thereof, wherein X, Het1, R1, R2, R3, R4 and R5 are as defined in the description. 15 Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

Подробнее
02-05-2013 дата публикации

6-Substituted isoquinolines and isoquinolinones

Номер: US20130109715A1
Принадлежит: SANOFI

The invention relates to 6-substituted isoquinoline and isoquinolinone derivatives of the formula (I) t,21 2. The method according to wherein the disease is hypertension claim 1 , pulmonary hypertension claim 1 , fibroid liver claim 1 , liver failure claim 1 , nephropathy claim 1 , renal failure claim 1 , chronic obstructive pulmonary disease (COPD) claim 1 , cerebral vasospasm claim 1 , pain claim 1 , spinal cord injury claim 1 , erectile dysfunction claim 1 , blood vessel restenosis claim 1 , or cancer development and progression.3. The method according to for curative approaches associated with stem cell or induced pluripotent stem cell treatment claim 1 , improvement of recognition or for the treatment or prevention of fibroid heart claim 1 , depression claim 1 , epilepsy claim 1 , renal papillary necrosis claim 1 , tubulo-interstitial dysfunction claim 1 , multiple sclerosis claim 1 , vessel stenosis or lipid disorders.6. The method according to any one of to wherein in formula (I) Ris NH.7. The method according to any one of to wherein in formula (I) Ris H claim 1 , halogen claim 1 , (C-C)alkyl claim 1 , or NHR′ claim 1 , wherein (C-C)alkyl and R′ are unsubstituted or substituted.8. The method according to any one of to wherein in formula (I) Ris H claim 1 , halogen claim 1 , (C-C)alkyl or (C-C)alkenyl-phenyl claim 1 , wherein (C-C)alkyl or phenyl are unsubstituted or substituted.9. The method according to any one of to wherein in formula (I) Ris H claim 1 , halogen claim 1 , (C-C)alkyl claim 1 , (C-C)aryl claim 1 , (C-C)cycloalkyl or (C-C)heteroaryl claim 1 , wherein (C-C)alkyl claim 1 , (C-C)cycloalkyl claim 1 , (C-C)aryl claim 1 , or (C-C)heteroaryl are unsubstituted or substituted.10. The method according to any one of to wherein in formula (I) Ris H claim 1 , halogen claim 1 , (C-C)alkyl claim 1 , O—(C-C)alkyl claim 1 , or R′ claim 1 , wherein (C-C)alkyl or R″ are unsubstituted or substituted.11. The method according to any one of to wherein in formula (I ...

Подробнее
02-05-2013 дата публикации

N-aminotetrahydroisoquinolines as anti-cancer agents

Номер: US20130109716A1

The compounds herein disclosed are tetrahydroisoquinoline analogs that have modifications on the phenyl rings by introducing groups with various electronic properties. These derivatives of tetrahydroisoquinoline have been shown to have anti-proliferative activity against cells. In particular, the compounds have been found to be effective in inhibiting the proliferation of cancer cells, such as cancer cells that originated in breast tissue. Additionally, it has been shown that the novel compounds have IC 50 values against the breast cancer cells that are 6-10-fold less than the IC 50 of tamoxifen.

Подробнее
09-05-2013 дата публикации

NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A

Номер: US20130116229A1
Принадлежит:

The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders. 2. The compound of claim 1 , where Ris selected from the group consisting of halogen claim 1 , CN claim 1 , OH claim 1 , C-C-alkyl claim 1 , fluorinated C-C-alkyl claim 1 , C-C-alkoxy claim 1 , fluorinated C-C-alkoxy claim 1 , C-C-cycloalkyl claim 1 , fluorinated C-C-cycloalkyl claim 1 , N(R)(R) claim 1 , C-C-alkyl-N(R)(R) claim 1 , C(O)O—R claim 1 , C(O)N(R)(R) claim 1 , N(R)S(O)(R) and S(O)N(R)(R).3. The compound of claim 1 , where Xis C—H.4. The compound of claim 1 , where Xis N.5. The compound of claim 1 , where Xis C—R.6. The compound of claim 1 , where Xis N.7. The compound of claim 1 , where Y is O.8. The compound of claim 1 , where Ris C-C-alkyl claim 1 , C-C-cycloalkyl or C-C-cycloalkylmethyl.9. The compound of claim 8 , where Ris a radical of the formula CHRR claim 8 , where Ris selected from the group consisting of hydrogen and C-C-alkyl and where Ris selected from the group consisting of C-C-alkyl.10. The compound of claim 1 , where Ris a moiety Z—Ar.11. The compound of claim 1 , where Ris a radical of the formula CRRR.12. The compound of claim 11 , where{'sup': 21', '22', 'g', 'h', 'h', 'g, 'sub': '2', 'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'Rand Rtogether with the carbon atom, to which they are bound form a saturated 5- to 7-membered carbocyclic ring or a saturated 5- to 7-membered heterocyclic ring which has 1, 2 or 3 heteroatoms or heteroatom containing groups selected from the group of O, N, S, SO and SOas ring members, where the carbocyclic ring and the heterocyclic ring may be unsubstituted or may be substituted by 1, 2 or 3 identical or different ...

Подробнее
09-05-2013 дата публикации

ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS

Номер: US20130116277A1
Принадлежит:

The present invention relates to a novel class of AKR1C3 inhibitors, to compositions containing them, to methods for their preparation, and to methods of use thereof. The AKR1C3 inhibitors may be useful in the treatment of, for example, prostate cancer, benign prostate hyperplasia (BPH), lung cancer, acne, seborrhea, hirsuitism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, uterine cancer, uterine fibroids, endometriosis, myeloma and leiomyoma. 3. The method of claim 2 , wherein said compound is selected from:6-hydroxy-2-(4-hydroxyphenyl)-4-phenylisoquinolin-1(2H)-one (15a),6,8-dihydroxy-2-(4-hydroxyphenyl)-4-(4-methoxyphenyl)isoquinolin-1(2H)-one (15g),6,8-dihydroxy-2-(4-hydroxyphenyl)-4-phenylisoquinolin-1(2H)-one (15h),(E)-3-(6,8-dihydroxy-2-(4-hydroxyphenyl)-1-oxo-1,2-dihydroisoquinolin-4-yl)acrylic acid (15l),2-(4-bromomethyl)phenyl-6-hydroxy-4-(4-hydroxyphenyl)isoquinolin-1(2H)-one (11),6-hydroxy-2-(4-hydroxyphenyl)-4-(4-(trifluoromethyl)phenylisoquinolin-1(2H)-one (13),6-hydroxy-2-(4-(hydroxymethyl)phenyl)-4-(4-hydroxyphenyl)isoquinolin-1(2H)-one (14),2-(4-(bromomethyl)-3-hydroxyphenyl)-6-hydroxy-4-(4-(trifluoromethyl)phenyl)isoquinolin-1(2H)-one (26),6-hydroxy-2-(4-hydroxyphenyl)-1-oxo-4-(3,4,5-trifluorophenyl)-1,2-dihydroisoquinoline-8-carbonitrile (85),3-(4-(3-fluoro-4-(trifluoromethyl)phenyl)-6-hydroxy-1-oxoisoquinolin-2(1H)-yl)benzamide (214) and4-(4-(3-fluoro-4-(trifluoromethyl)phenyl)-6-hydroxy-1-oxoisoquinolin-2(1H)-yl)benzamide (215).4. The method according to claim 3 , wherein said administration selectively inhibits an AKR1C3 enzyme activity.7. The method of claim 6 , wherein said compound is selected from:6-hydroxy-2-(4-hydroxyphenyl)-4-phenylisoquinolin-1(2H)-one (15a),6,8-dihydroxy-2-(4-hydroxyphenyl)-4-(4-methoxyphenyl)isoquinolin-1(2H)-one (15g),6,8-dihydroxy-2-(4-hydroxyphenyl)-4-phenylisoquinolin-1(2H)-one (15h),(E)-3-(6,8-dihydroxy-2-(4-hydroxyphenyl)-1-oxo-1,2-dihydroisoquinolin-4-yl ...

Подробнее
16-05-2013 дата публикации

Process for the preparation of 2-(cyclohexylmethyl)-n--1,2,3,4-tetrahydroisoquinoline-7-sulfonamide

Номер: US20130123302A1
Принадлежит: SANOFI SA

Industrially applicable process for preparing 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide, and salts thereof.

Подробнее
16-05-2013 дата публикации

Process for Synthesizing Substituted Isoquinolines

Номер: US20130123503A1
Принадлежит: Bristol Myers Squibb Co

The present disclosure generally relates to a process for synthesizing optionally substituted 1-chloro-4-methoxyisoquinolines. The present disclosure also relates to intermediates useful in this process.

Подробнее
23-05-2013 дата публикации

SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS

Номер: US20130131018A1
Принадлежит: Exonhit S.A.

The present invention relates generally to substituted isoquinolines and their use as tubulin polymerization inhibitors. In particular, the invention relates to substituted isoquinolines which possess useful therapeutic activity, use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds. 117.-. (canceled)19. The compound according to wherein:{'sup': '+', 'sub': 1', '6, 'X represents N or N—Z, wherein Z is selected in the group consisting of a (C-C)alkyl, an aryl and an acyl;'}{'sub': 1', '1', '5, 'claim-text': wherein Ra represents a NRa′Ra″ or ORa′″ group;', {'sub': 1', '5, 'wherein Ra′ and Ra″, independently from each other, are selected from the group consisting of H and (C-C)alkyl;'}, {'sub': 1', '5, 'wherein Ra′″ represents H or (C-C)alkyl;'}], 'Rrepresents H, CN, a CORa or a (C-C)alkyl;'}{'sub': 3', '2', '1', '5, 'claim-text': wherein Rb represents a NRb′Rb″ or ORb′″ group;', {'sub': 1', '5, 'wherein Rb′ and Rb′, independently from each other, are selected from the group consisting of H and (C-C)alkyl;'}, {'sub': 1', '5, 'wherein Rb′″ represents H or (C-C)alkyl;'}], 'Rrepresents H, CN, OH, a CORb, NHor a (C-C)alkyl;'}{'sub': 7', '1', '5', '1', '5', '1', '5', '1', '5', '1', '5, 'Rrepresents a (C-C)alkyl, a (C-C)alkoxy, a (C-C)alkylthio, a (C-C)alkylamino, a (C-C)dialkylamino;'}{'sub': 8', '1', '6', '2, 'claim-text': [{'sub': 1', '6', '2', '6', '2, 'wherein R and R′, independently from each other, are selected from the group consisting of H, a (C-C)alkyl, a (C-C)alkenyl, an acyl, an aryl, a heterocyclyl, amino acid, a Y—SOgroup, a P(O)(OG)(OG′) group,'}, {'sub': 1', '6', '2', '1', '6', '1', '6', '1', '6, 'wherein Y is selected in the group consisting of a hydrogen atom, (C-C)alkyl, NH, (C-C)alkylamino, di(C-C)alkylamino and (C-C)alkoxycarbonylamino;'}, {'sub': 1', '6, 'wherein G and G′, independently from each other, are selected in the group consisting of H, (C-C)alkyl and aryl;'}], ' ...

Подробнее
23-05-2013 дата публикации

LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY

Номер: US20130131321A1
Принадлежит: GRAFFINITY PHARMACEUTICALS GMBH

The present invention relates to the use for affinity purification of an antibody or an fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material, the ligand being represented by formula (I) 2. The use of wherein Aris phenylene claim 1 , preferably methoxy-substituted phenylene.3. The use of wherein the C═O and the NH group are bonded to Arin meta position to each other.4. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Aris attached to the C═O group via a carbon ring atom which is adjacent to a ring heteroatom claim 1 , preferably a nitrogen or oxygen atom.5. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Arcontains two or more nitrogen atoms or one or more nitrogen atoms and an oxygen atom.6. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Aris N-methyl-substituted pyrazole claim 5 , pyridine claim 5 , isoxazole or oxadiazole.7. The use according to wherein the support material comprises a material selected from carbohydrates or crosslinked carbohydrates claim 1 , preferably agarose claim 1 , cellulose claim 1 , dextran claim 1 , starch claim 1 , alginate and carrageenan claim 1 , Sepharose claim 1 , Sephadex; synthetic polymers claim 1 , preferably polystyrene claim 1 , styrene-divinylbenzene copolymers claim 1 , polyacrylates claim 1 , PEG-Polycacrylate copolymers polymethacrylates claim 1 , polyvinyl alcohol claim 1 , polyamides and perfluorocarbons; inorganic materials claim 1 , preferably glass claim 1 , silica and metal oxides; and composite materials.8. The use according to wherein the protein is an antibody claim 1 , preferably an IgG type antibody claim 1 , or an Fc fusion protein.9. The use of wherein the purification is attained by binding of the ligand of the ligand-substituted matrix to an Fc fragment or domain of the antibody or the fusion protein.10. The use according to wherein the Fc ...

Подробнее
30-05-2013 дата публикации

4-carboxybenzylamino derivatives as histone deacetylase inhibitors

Номер: US20130137690A1
Принадлежит: Individual

The present invention relates to a novel class of 4-carboxybenzylamino derivatives. The 4-carboxybenzylamino compounds can be used to treat cancer. The 4-carboxybenzylamino compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the 4-carboxybenzylamino derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the 4-carboxybenzylamino derivatives in vivo.

Подробнее
30-05-2013 дата публикации

Process for the preparation of 2-(cyclohexylmethyl)-n--1,2,3,4-tetrahydroisoquinoline-7-sulfonamide

Номер: US20130137718A1
Автор: Steven Elenbaas
Принадлежит: SANOFI SA

Industrially applicable process for preparing 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide, and salts thereof.

Подробнее
30-05-2013 дата публикации

Novel 6,7-disubstituted-sioquinoline derivatives and their use

Номер: US20130137719A1
Автор: Ekholm Matti, Takio Ville
Принадлежит: MONTISERA LTD

The present invention relates compounds of general formula (I) and stereoisomers and pharmaceutically acceptable salts and prodrugs thereof; wherein R′ and R-Rare as defined in the claims. The invention also relates to said compounds for use as a medicament and particularly in the treatment of drug addiction and CNS related diseases. 2. The compound of formula (I) as defined in claim 1 , wherein the dotted line is a bond and R claim 1 , Rand Rare H claim 1 , and Rand Rare F.3. The compound of formula (I) as defined in claim 1 , wherein Rand Rare H claim 1 , and R claim 1 , Rand Rare F.4. The compound of formula (I) as defined in claim 1 , wherein Rand Rare H claim 1 , Rand Rare F claim 1 , and Ris methyl.5. The compound of formula (I) as defined in claim 1 , wherein the compound is 6 claim 1 ,7-difluoro-1-methyl-3 claim 1 ,4-dihydroisoquinoline or a pharmaceutically acceptable salt thereof.6. The compound of formula (I) as defined in claim 1 , wherein the compound is 1-methyl-4 claim 1 ,6 claim 1 ,7-trifluoro-3 claim 1 ,4-dihydroisoquinoline or a pharmaceutically acceptable salt thereof.7. The compound of formula (I) as defined in claim 1 , wherein the compound is 4 claim 1 ,6 claim 1 ,7-trifuoro-1-methyl-1 claim 1 ,2 claim 1 ,3 claim 1 ,4-tetrahydroisoquinoline or a pharmaceutically acceptable salt thereof.8. A pharmaceutical composition comprising an effective amount of one or more compounds of formula (I) as defined in claim 1 , or a stereoisomer or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable carrier and suitable excipients.9. The compound of formula (I) as defined in claim 1 , or a stereoisomer or pharmaceutically acceptable salt thereof for use as a medicament.10. The compound of formula (I) as defined in claim 1 , or a stereoisomer or pharmaceutically acceptable salt thereof for use in the treatment of CNS related diseases.11. The compound of formula (I) as defined in claim 1 , or a stereoisomer or pharmaceutically ...

Подробнее
30-05-2013 дата публикации

One-Pot Preparation of Hexahydroisoquinolines from Amides

Номер: US20130137874A1
Принадлежит: Mallinckrodt LLC

The present invention provides an efficient process for the preparation of hexahydroisoquinolines from amides. In particular, the invention provides a good yielding, one-pot process for the synthesis of hexahydroisoquinolines. 3. The process of claim 1 , wherein:{'sub': 3', '211, 'Ris —OR;'}{'sub': 211', '212', '212', '3', '212', '2', '212, 'Ris chosen from hydrogen, alkyl, —C(O)R, —C(O)C(R), —C(O)NHR, and —SOR; and'}{'sub': '212', 'Ris chosen from alkyl and aryl.'}4. The process of claim 1 , wherein:{'sub': 4', '211, 'Ris —OR;'}{'sub': 211', '212', '212', '3', '212', '2', '212, 'Ris chosen from hydrogen, alkyl, —C(O)R, —C(O)C(R), —C(O)NHR, and —SOR; and'}{'sub': '212', 'Ris chosen from alkyl and aryl.'}5. The process of claim 1 , wherein:{'sub': 6', '211, 'Ris —OR;'}{'sub': 211', '212', '212', '3', '212', '2', '212, 'Ris chosen from hydrogen, alkyl, —C(O)R, —C(O)C(R), —C(O)NHR, and —SOR; and'}{'sub': '212', 'Ris chosen from alkyl and aryl.'}6. The process of claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Rare hydrogen; Rand Rare methoxy; Ris chosen from hydroxyl claim 1 , —OC(O)CH claim 1 , —C(O)C(CH) claim 1 , —OC(O)Ph claim 1 , and —OSOCH;{'sub': 12', '212, 'Ris chosen from alkyl, allyl, benzyl, and halo; and Ris methyl.'}7. The process of claim 1 , wherein:{'sub': 3', '4', '6', '211, 'R, R, and Rare —OR;'}{'sub': 211', '212', '212', '3', '212', '2', '212, 'Ris chosen from hydrogen, alkyl, —C(O)R, —C(O)C(R), —C(O)NHR, and —SOR; and'}{'sub': '212', 'Ris chosen from alkyl and aryl.'}8. The process of claim 1 , wherein the molar ratio of the compound comprising Formula (I) to POClis from about 1:0.5 to about 1:5.9. The process of claim 1 , wherein the asymmetric catalyst comprises a metal or a metal source and a chiral ligand claim 1 ,11. The process of claim 9 , wherein the metal source is dichloro(p-cymene) ruthenium(II) dimer and the chiral ligand is (1S claim 9 ,2S)-(+)-N-4-tolylsulfonyl-1 claim 9 ,2-diphenylethylene-1 claim 9 ...

Подробнее
06-06-2013 дата публикации

Novel hydroxamates as therapeutic agents

Номер: US20130142758A1
Принадлежит: Pharmacyclics LLC

The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

Подробнее
06-06-2013 дата публикации

Guanidine compound

Номер: US20130143860A1
Принадлежит: Astellas Pharma Inc

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.

Подробнее
20-06-2013 дата публикации

DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE

Номер: US20130158015A1
Принадлежит: AERIE PHARMACEUTICALS, INC.

Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved. 2. A compound according to claim 1 , wherein Ris hydrogen or C-Calkyl; B is C-Ccarbonyl; X claim 1 , X claim 1 , and Xare hydrogen; the double circle indicates an aromatic or heteroaromatic ring; and Z is a bond claim 1 , C-Calkyl claim 1 , C-Cheteroalkyl claim 1 , or an O atom.3. A compound according to claim 1 , wherein Z is a bond or —CH—.4. A compound according to claim 1 , wherein X claim 1 , Xand Xare each hydrogen.5. A compound according to claim 1 , wherein A is —CHCH—.6. A compound according to claim 1 , wherein Rand Rare independently hydrogen or methyl.7. A compound according to claim 1 , wherein Ris hydrogen or C-Calkyl.8. A pharmaceutical composition comprising a compound according to and a pharmaceutically acceptable carrier.9. A method for treating a disease in a subject comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering to a subject an effective amount of a compound according to ; wherein the disease comprises eye disease.'}10. The method of claim 9 , wherein the eye disease comprises glaucoma or a neurodegenerative eye disease.11. A method of modulating kinase activity comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'contacting a cell with a compound according to in an amount effective to modulate kinase activity.'}12. The method of claim 11 , wherein the cell is in a subject.13. A method of reducing intraocular pressure comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'contacting a cell with a compound according to in ...

Подробнее
11-07-2013 дата публикации

NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Номер: US20130178417A1
Принадлежит:

The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. 25.-. (canceled)6. A compound as in claim 1 , wherein Ris selected from the group consisting of hydrogen claim 1 , alkyl claim 1 , substituted alkyl claim 1 , halo claim 1 , alkoxy claim 1 , aryloxy claim 1 , substituted aryloxy claim 1 , substituted aryl claim 1 , alkylthio claim 1 , aminoacyl claim 1 , aryl claim 1 , substituted amino claim 1 , heteroaryl claim 1 , heteroaryloxy claim 1 , —S(O)-aryl claim 1 , —S(O)-substituted aryl claim 1 , —S(O)-heteroaryl claim 1 , and —S(O)-substituted heteroaryl claim 1 , where n is zero claim 1 , one or two.7. A compound as in claim 6 , wherein Ris selected from the group consisting of:(4-methoxy)phenylsulfonylamino;2,6-dimethylphenoxy;3,4-difluorophenoxy;3,5-difluorophenoxy;3-chloro-4-fluorophenoxy;3-methoxy-4-fluorophenoxy;3-methoxy-5-fluorophenoxy;4-(methylsulfonamido)phenoxy;4-(phenylsulfonamido)phenoxy;{'sub': '3', '4-CF—O-phenoxy;'}{'sub': '3', '4-CF-phenoxy;'}4-chlorophenoxy;4-fluorophenoxy;4-(4-fluorophenoxy)phenoxy;4-methoxyphenoxy;4-nitrophenoxy;benzyloxy;bromo;butoxy,{'sub': '3', 'CF;'}chloro;cyclohexyloxy;cyclohexylsulfanyl;cyclohexylsulfonyl;fluoro;hydrogen;iodo;isopropoxy;methyl;phenoxy;phenyl;phenylsulfanyl;phenylsulfinyl;phenylsulfonyl;phenylurea;pyridin-1-ylsulfanyl;pyridin-3-yloxy; andpyridin-4-ylsulfanyl.8. A compound as in claim 1 , wherein Ris selected from the group consisting of substituted amino claim 1 , aryloxy claim 1 , substituted aryloxy claim 1 , alkoxy claim 1 , substituted alkoxy claim 1 , halo claim 1 , hydrogen claim 1 , alkyl claim 1 , substituted alkyl claim 1 , aryl claim 1 , —S(O)-aryl claim 1 , —S(O)-substituted aryl claim 1 , —S(O)-cycloalkyl claim 1 , where n is zero claim 1 , one or two claim 1 , aminocarbonylamino claim 1 , heteroaryloxy claim 1 , and cycloalkyloxy.9. A ...

Подробнее
11-07-2013 дата публикации

Cannabinoid receptor modulators

Номер: US20130178457A1
Принадлежит: Lupin Ltd

Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors of Formula (I).

Подробнее
11-07-2013 дата публикации

CHIRAL AUXILIARIES

Номер: US20130178612A1
Принадлежит: CHIRALGEN, LTD.

Chiral auxiliaries useful for efficiently producing a phosphorus atom-modified nucleic acid derivative with high stereoregularity, and compounds represented by the following the general formula (I) or the general formula (XI) for introducing the chiral auxiliaries. 2. The compound or a salt thereof according to claim 1 , wherein Rand Rare hydrogen atom or an alkyl group claim 1 , Ris phenyl group claim 1 , Rand Rare hydrogen atom or an alkyl group claim 1 , and Y is —C(R)(R)— (Rand Rare independently hydrogen atom or an alkyl group claim 1 , and when Rrepresents an alkyl group claim 1 , Rmay bind with the phenyl group represented by Rto form a ring) claim 1 , o-phenylene group claim 1 , or naphthalene-1 claim 1 ,2-diyl group.8. The method according to claim 7 , wherein 3% dichloroacetic acid (DCA) in dichloromethane is used for the acidic condition in the step (c).9. The method according to claim 7 , wherein claim 7 , as the modification of phosphorus atom claim 7 , a group represented by X (X represents an alkylthio group which may have a substituent claim 7 , an alkenylthio group which may have a substituent claim 7 , an alkynylthio group which may have a substituent claim 7 , an arylthio group which may have a substituent claim 7 , thiol group claim 7 , an alkoxy group which may have a substituent claim 7 , —BH claim 7 , —Se claim 7 , an alkyl group which may have a substituent claim 7 , an alkenyl group which may have a substituent claim 7 , an alkynyl group which may have a substituent claim 7 , an aryl group which may have a substituent claim 7 , an acyl group which may have a substituent claim 7 , or —N(R)(R) (Rand Rindependently represent hydrogen atom claim 7 , an alkyl group which may have a substituent claim 7 , an alkenyl group which may have a substituent claim 7 , an alkynyl group which may have a substituent claim 7 , or an aryl group which may have a substituent) is introduced on the phosphorus atom.11. The compound or a salt thereof according to ...

Подробнее
18-07-2013 дата публикации

COMPOUNDS THAT INHIBIT (BLOCK) BITTER TASTE IN COMPOSITION AND METHODS OF MAKING SAME

Номер: US20130183252A1
Принадлежит: Senomyx, Inc.

The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in, e.g., coffee. Also, the invention relates to the discovery of specific compounds and compositions containing that function as bitter taste blockers and the use thereof as bitter taste blockers or flavor modulators in, e.g., coffee and coffee flavored foods, beverages and medicaments. Also, the present invention relates to the discovery of a compound that antagonizes numerous different human T2Rs and the use thereof in assays and as a bitter taste blocker in compositions for ingestion by humans and animals. 2. The compound of claim 1 , wherein X is selected from the group consisting of hydrogen claim 1 , heteroalkyl claim 1 , substituted heteroalkyl claim 1 , heteroaryl claim 1 , substituted heteroaryl claim 1 , heteroarylalkyl claim 1 , substituted heteroarylalkyl claim 1 , CN claim 1 , S(O)R claim 1 , CONRR claim 1 , —COR claim 1 , SONRR claim 1 , NRSOR claim 1 , NRSONRR claim 1 , B(OR)(OR) claim 1 , P(O)(OR)(OR) claim 1 , and P(O)(R)(OR).7. A composition comprising one or more compounds of claim 1 , or a salt claim 1 , hydrate claim 1 , solvate or N oxide thereof claim 1 , and one or more pharmaceutically acceptable carriers.8. The composition of claim 7 , which is a food claim 7 , beverage or medicament for human consumption.9. A coffee or coffee flavored food or beverage or medicament composition that comprises at least one compound of or a salt claim 1 , hydrate claim 1 , solvate or N oxide thereof.10. The composition of claim 9 , which is an instant coffee claim 9 , ground coffee claim 9 , or brewed coffee.11. The composition of claim 9 , which is an instant coffee.12. A food claim 1 , beverage claim 1 , or medicament composition having a bitter taste wherein said bitter taste is alleviated or eliminated by the addition of an effective amount of a compound of or a salt claim 1 , hydrate claim 1 , ...

Подробнее
18-07-2013 дата публикации

Derivatives of Betulin

Номер: US20130184263A1
Принадлежит: GlaxoSmithKline LLC

The present invention relates to compounds characterized by having a structure according to the following Formula I: 2. The compound of claim 1 , wherein Land Lare both [C(RR′)].3. The compound of claim 1 , wherein Land Lare both —CH—.4. The compound of claim 1 , wherein each instance of q is independently 1 claim 1 , 2 claim 1 , or 3.5. The compound of claim 1 , wherein q is 1.6. The compound of claim 1 , wherein W is O.7. The compound of claim 1 , wherein W is a bond.8. The compound of claim 1 , wherein when W is a bond claim 1 , then Ris —H.9. The compound of claim 1 , wherein when W is O claim 1 , then Ris —H.10. The compound of claim 1 , wherein Qin the A group is absent and Qin the A group is —CH— and the Q in the Formula I structure is —C(═O)—.11. The compound of claim 1 , wherein Ris —H.12. The compound of claim 1 , wherein Ris —(CH)NRR.13. The compound of claim 1 , wherein Ris (dimethylamino)ethyl.14. The compound of claim 1 , wherein each instance of r is independently 0 claim 1 , 1 claim 1 , 2 claim 1 , or 3.15. The compound of claim 1 , wherein r is 2.17. The compound of claim 1 , wherein X is a monocyclic (C-C)aryl.18. The compound of claim 1 , wherein X is phenyl.19. The compound of claim 1 , wherein Ris —H.20. The compound of claim 1 , wherein each instance of m is independently 0 or 1.21. The compound of claim 1 , wherein m is 0.22. The compound of claim 1 , wherein m is 1.23. The compound of claim 1 , wherein n is 1.24. The compound of claim 1 , wherein Rand R′ are both —H.25. The compound of claim 1 , wherein Rand Rare both (C-C)alkyl.26. The compound of claim 1 , wherein Ris methyl.27. The compound of claim 1 , wherein Ris methyl.28. The compound of claim 1 , wherein Rand Rare both methyl.29. The compound of claim 1 , wherein Ris halo.30. The compound of claim 1 , wherein Ris selected from chloro claim 1 , bromo claim 1 , or fluoro.31. The compound of claim 1 , wherein Ris chloro.32. The compound of claim claim 1 , wherein Ris absent.33. The ...

Подробнее
08-08-2013 дата публикации

ACYLSULFONAMIDES AND PROCESSES FOR PRODUCING THE SAME

Номер: US20130203709A1
Принадлежит:

The present disclosure relates to acylsulfonamides and processes for their preparation. The processes involve a target-guided synthesis approach, whereby a thioacid and a sulfonyl azide are reacted in the presence of a biological target protein, a Bcl-2 family protein, to form the acylsulfonamide. 2. The compound of wherein the Bcl-2 family protein is Mcl-1.3. A composition comprising a Bcl-2 claim 1 , Bcl-XL claim 1 , and/or Bcl-w inhibitor; and an Mcl-1 and/or A1/Bfl-1 inhibitor claim 1 , wherein at least one inhibitor is the compound of .4. A method of treating or preventing cancer claim 1 , the method comprising administering the compound of .5. A compound comprising a first fragment selected from SZ1 to SZ31 and a second fragment selected from TA1 to TA15.6. The compound of having the formula selected from SZ31TA2 claim 5 , SZ15TA2 claim 5 , and SZ17TA2.7. A method of screening for an inhibitor claim 5 , as described herein.8. The method of comprising contacting a fragment library with a Bcl-2 family protein.9. The method of wherein the Bcl-2 family protein is selected from one or more of Bcl-2 claim 8 , Bcl-XL claim 8 , Bcl-w claim 8 , Mcl-1 claim 8 , and A1/Bfl-1.10. The method of wherein the Bcl-2 family protein is Mcl-1.11. The compound of claim 1 , wherein Zis aryl claim 1 , substituted aryl claim 1 , or heteroaryl.13. The compound of claim 1 , wherein Z claim 1 , Z claim 1 , Z claim 1 , Z claim 1 , and Zare independently hydrogen claim 1 , hydrocarbyl claim 1 , substituted hydrocarbyl claim 1 , amino claim 1 , alkoxy claim 1 , nitro claim 1 , or trihalomethoxy.15. The compound of claim 1 , wherein Zis substituted or unsubstituted furyl claim 1 , thienyl claim 1 , pyridyl claim 1 , oxazolyl claim 1 , isoxazolyl claim 1 , imidazolyl claim 1 , pyridyl claim 1 , pyrimidyl claim 1 , purinyl claim 1 , triazolyl claim 1 , or thiazolyl.16. The compound of claim 1 , wherein Zis substituted or unsubstituted morpholino claim 1 , pyran claim 1 , tetrahydropyran claim ...

Подробнее
08-08-2013 дата публикации

COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES

Номер: US20130203733A1
Принадлежит:

The present invention is based, in part, on assays we conducted that revealed compounds that may be used to treat or prevent diseases characterized by an abnormal or undesirable association of one protein with another. 2. The composition of claim 1 , wherein Z is O.3. The composition of claim 1 , wherein Y is NR.4. The composition of claim 1 , wherein Ris H.5. The composition of claim 1 , wherein Y is CRR.6. The composition of claim 1 , wherein each Rand Ris independently halo or hydroxy.79-. (canceled)10. The composition of claim 1 , wherein{'sup': '22', 'Ris halo; and'}q is 1.11. The composition of claim 10 , wherein p is 0.12. The composition of claim 10 , wherein Ris bromo.1324-. (canceled)25. A pharmaceutical composition comprising:4-Bromo-N-(4-bromo-phenyl)-3-cyclohexylsulfamoyl-benzamide;N-(4-Bromo-phenyl)-3-(4-bromo-phenylsulfamoyl)-benzamide;3-(4-Bromo-phenylsulfamoyl)-N-phenyl-benzamide;4-Bromo-3-cyclohexylsulfamoyl-N-phenyl-benzamide;N-(4-Bromo-phenyl)-3-cyclohexylsulfamoyl-benzamide; or1-[3-(Azepane-1-sulfonyl)-2-bromo-phenyl]-2-(3-hydroxy-phenyl)-ethanone.2628-. (canceled)29. A method of treating a subject who has been diagnosed as having claim 1 , or who is at risk of developing claim 1 , a disorder characterized by an undesirable association of proteins claim 1 , the method comprising identifying the subject and administering to the subject a therapeutically effective amount of the pharmaceutical composition of .30. The method of claim 29 , wherein the subject has been diagnosed as having claim 29 , or is at risk of developing claim 29 , Huntington's disease.31. The method of claim 29 , wherein the subject has been diagnosed as having claim 29 , or is at risk of developing claim 29 , Parkinson's disease.32. The method of claim 29 , wherein the subject has been diagnosed as having claim 29 , or is at risk of developing claim 29 , spinal and bulbar muscular atrophy claim 29 , dentatorubral-pallidoluysian atrophy claim 29 , spinocerebellar ataxia type 1 ...

Подробнее
08-08-2013 дата публикации

Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy

Номер: US20130203749A1
Принадлежит:

The present invention relates to tetrahydroisoquinoline of the formula (I) 3. Compound as claimed in claim 1 , wherein Ris hydrogen claim 1 , halogen or C-C-alkoxy.5. Compound as claimed in claim 1 , wherein Ris hydrogen or C-C-alkyl.6. Compound as claimed in claim 1 , wherein Ris hydrogen claim 1 , C-C-alkyl claim 1 , halogenated C-C-alkyl claim 1 , amino-C-C-alkyl claim 1 , CHCN claim 1 , C-C-alkylcarbonyl claim 1 , (halogenated C-C-alkyl)carbonyl claim 1 , —C(═NH)NH claim 1 , —C(═NH)NHCN claim 1 , C-C-alkylsulfonyl claim 1 , amino claim 1 , —NO or C-C-heterocyclyl.7. Compound as claimed in claim 1 , wherein Ris C-C-alkyl and Ris hydrogen or C-C-alkyl claim 1 , or wherein R claim 1 , Rtogether are optionally substituted C-C-alkylene.8. Compound as claimed in claim 1 , wherein Ris optionally substituted C-C-aryl.10. Compound as claimed in claim 1 , wherein Ris optionally substituted C-C-heterocyclyl.12. Compound as claimed in claim 1 , which is:1-[1-(4-Chlorophenyl)cyclobutyl]-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile;1-[2-(4-Chlorophenyl)propan-2-yl]-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile; and1-[1-(Pyridin-2-yl)cyclobutyl]-1,2,3,4-tetrahydroisoquinoline-7-carbonitrile.13. Pharmaceutical composition which comprises a carrier and a compound of .14. A method for treating a neurologic or psychiatric disorder in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of claim 1 , wherein the neurologic disorder is selected from the group consisting of dementia claim 1 , cognitive impairment claim 1 , and attention deficit disorder claim 1 , and wherein the psychiatric disorder is selected from the group consisting of anxiety disorder claim 1 , depression claim 1 , bipolar disorder claim 1 , schizophrenia claim 1 , and psychosis. This application is a divisional of U.S. application Ser. No. 12/933,326 filed on Dec. 20, 2010 which is the U.S. National Stage of International Patent ...

Подробнее
05-09-2013 дата публикации

ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Номер: US20130231333A1
Принадлежит: ARAGON PHARMACEUTICALS, INC.

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors. 2. The compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , or N-oxide thereof claim 1 , wherein:ring A is 5- or 6-membered monocyclic heteroaryl or 8-, 9- or 10-membered bicyclic heterocycle;ring B is phenyl, naphthyl, 5- or 6-membered monocyclic heteroaryl or 8-, 9- or 10-membered bicyclic heterocycle;ring C is phenyl, or 5- or 6-membered monocyclic heteroaryl;{'sup': 3', '8', '8′', '9', '9', '10', '10', '10', '9', '10', '10', '9', '9, 'sub': 2', '2', '2', '2', '2', '2', '1', '4', '2', '4', '2', '4', '1', '4', '1', '4', '1', '4', '1', '4, 'each Ris independently selected from H, halogen, —NRR, —CN, —OH, —OR, —SR, —S(═O)R, —S(═O)R, —NHS(═O)R, —S(═O)N(R), —C(═O)R, —OC(═O)R, —COR, —C(═O)N(R), C-Calkyl, C-Calkenyl, C-Calkynyl, C-Cfluoroalkyl, C-Cheteroalkyl, C-Cfluoroalkoxy, and C-Calkoxy;'}{'sup': 4', '8', '8′', '9', '9', '10', '10', '10', '9', '10', '10', '9', '10', '9', '9', '9', '9', '9', '10', '9', '10, 'sub': 2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '1', '6', '2', '6', '2', '6', '1', '6', '1', '6', '1', '6', '1', '6, 'each Ris independently selected from H, halogen, —NO, —NRR, —CN, —OH, —OR, —SR, —S(═O)R, —S(═O)R, —NHS(═O)R, —S(═O)N(R), —C(═O)R, —OC(═O)R, —COR, —OCOR, —C(═O)N(R), —OC(═O)N(R), —NRC(═O)N(R), —NRC(═O)R, —NRC(═O)OR, substituted or unsubstituted C-Calkyl, substituted or unsubstituted C-Calkenyl, substituted or unsubstituted C-Calkynyl, substituted or unsubstituted C-Cfluoroalkyl, substituted or unsubstituted C-Cheteroalkyl, substituted or unsubstituted C-Cfluoroalkoxy, substituted or unsubstituted C-Calkoxy, substituted or unsubstituted phenyl and ...

Подробнее
19-09-2013 дата публикации

Synthesis of Tripodal Catechol Derivatives Having an Adamantyl Basic Framework for Functionalizing Surfaces

Номер: US20130245269A1
Принадлежит: Justus Liebig Universitaet Giessen

The present invention describes tripodal catechol derivatives with an adamantyl basic framework for the functionalisation of surfaces, methods for their production and use. The remaining fourth bridgehead position is easily suitable to be further functionalised via so-called click reactions, by way of example with biomolecules, dyes, radiomarkers, polyethylene glycol or active agents. The compounds according to the present invention have the general formula X-Ad[(CH 2 ) n —YZ] 3 , wherein A stands for the adamantyl skeleton, X stands for a group —(CH 2 ) p —R 5 , wherein p=0 to 10 and R 5 is selected from —H, —NH 2 , —NO 2 , —OH, —SH, —O—NH 2 , —NH—NH 2 , —N═C═S—, —N═C═O—, —CH═CH 2 , —C≡CH, —COOH, —(C═O)H, —(C═O)R 6 Y stands for —CH 2 —, —CH═CH—, —O—, —S—, —S—S—, —NH—, —O—NH—, —NH—O—, —HC═N—O—, —O—N═CH—, —NR 1 —, -aryl-, -heteroaryl-, —(C═O)—, —O—(C═O)—, —(C═O)—O—, —NH—(C═O)—, —(C═O)—NH—, —NR 1 —(C═O)—, —(C═O)—NR 1 —, —NH—(C═O)—NH—, —NH—(C═S)—NH—, R 1 stands for an alkyl group, R 6 for an alkyl, alkenyl, alkynyl, aryl or heteroaryl group, and Z stands for a catechol derivative. The production of the compounds occurs by reacting a compound X-Ad[(CH 2 ) n —Y′] 3 with a reagent Y″Z to the corresponding compound X-Ad[(CH 2 ) n —YZ] 3 and subsequently purifying the reaction product. Y′ and Y″ are hereby precursors of Y. The compounds according to formula (I) according to the present invention are suitable to be used in a method to functionalise surfaces. The X group of the compounds according to the present invention is suitable to be optionally coupled to an effector, for example, by means of click chemistry.

Подробнее
26-09-2013 дата публикации

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT FIBROSIS

Номер: US20130253004A1
Принадлежит: Amira Pharmaceuticals, Inc.

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases. 2. The compound of claim 1 , wherein:{'sup': 1', 'D', '10', '9', '10, 'sub': 2', '2', '2', '2', '2', '2', '2', '3, 'Ris —COH, —COR, —C(═O)NHSOR, —C(═O)N(R), —SONHC(═O)R, —CN, —C(═O)NHCHCHSOH, tetrazolyl or 5-oxo-2,5-dihydro-[1,2,4]oxadiazol-3-yl;'}{'sup': '1', 'sub': 1', '6', '3', '6', '1', '4', '3', '6', '3', '6', '1', '4, 'Lis absent, C-Calkylene, —C-Ccycloalkylene-, —C-Calkylene-C-Ccycloalkylene-, or —C-Ccycloalkylene-C-Calkylene-;'}ring A is phenyl furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl.{'sup': '3', 'sub': 1', '4, 'Ris H or C-Calkyl;'}{'sup': 2', '2', '2', 'C, 'sub': 3', '6, 'Ris substituted or unsubstituted C-Ccycloalkyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted monocyclic heteroaryl, wherein if Ris substituted then Ris substituted with 1, 2 or 3 R;'}n is 0 or 1;p is 0 or 1.3. The compound of wherein:{'sup': 1', 'D', '10, 'sub': 2', '2', '2, 'Ris —COH, —COR, or —C(═O)NHSOR;'}{'sup': '1', 'sub': 2', '3', '3', '2', '2', '3', '2', '3', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2, 'Lis absent, —CH—, —CH(CH)—, —C(CH)—, —CH(CHCH)—, —C(CHCH)—, —CHCH—, —CHCHCH—, cyclopropyl-1,1-diyl, cyclopropyl-1,2-diyl, cycloprop-2-enyl-1,1-diyl, cyclobutyl-1,1-diyl, cyclopentyl-1,1-diyl, cyclohexyl-1,1-diyl, —C(CHCH)CH— or —CHC(CHCH);'}{'sup': 2', '2', '2', 'C, 'Ris a substituted or unsubstituted phenyl, wherein if Ris substituted then Ris substituted with 1, 2 or 3 R.'}5. The compound of wherein:{'sup': 2', '2', '2', '12', '12, 'sub': 3', '6', '3', '6', '3', ...

Подробнее
26-09-2013 дата публикации

SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY

Номер: US20130253005A1
Принадлежит:

Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents. 3. The pharmaceutical composition of claim 1 , further comprising a DNA cross-linking agent.4. The pharmaceutical composition of claim 1 , further comprising a poly(adenosine diphosphate (ADP)-ribose)polymerase (PARP) inhibitor7. The pharmaceutical composition of claim 5 , further comprising a DNA cross-linking agent.8. The pharmaceutical composition of claim 5 , further comprising a poly(adenosine diphosphate (ADP)-ribose)polymerase (PARP) inhibitor.10. The pharmaceutical composition of claim 9 , further comprising a poly(adenosine diphosphate (ADP)-ribose)polymerase (PARP) inhibitor.11. (canceled)13. (canceled)15. (canceled)1821-. (canceled)2326-. (canceled)2830-. (canceled)32. (canceled)34. (canceled)36. A method to identify a cancer that is responsive to ubiquitin specific protease 1 (USP1) inhibition claim 9 , comprising{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'contacting cancer cells from a cancer with a small molecule inhibitor of USP1 according to Formula I of'}or a pharmaceutically acceptable salt thereof; andmeasuring USP1 activity in the cancer cells contacted with the small molecule inhibitor of USP1,wherein reduced USP1 activity in the cancer cells contacted with the small molecule inhibitor of USP1 relative to control USP1 activity in the cancer cells not contacted with the small molecule inhibitor of USP1 identifies the cancer as a cancer that that is responsive to USP1 inhibition.37. (canceled)38. A method to identify a cancer that is responsive to ubiquitin specific protease 1 (USP1) inhibition claim 9 , comprising{'claim-ref': {'@idref': 'CLM-00005', 'claim 5'}, 'contacting cancer cells from a cancer with a small molecule inhibitor of USP1 ...

Подробнее
10-10-2013 дата публикации

Aromatic ketone synthesis with amide reagents and related reactions

Номер: US20130267712A1
Принадлежит: Northern Illinois University

A method of preparing an aryl carbonyl or aryl thiocarbonyl compound, comprises reacting an N-(nitroaryl)-amide or N-(nitroaryl)-thioamide with an aromatic ring, with a superacid catalyst, to produce the aryl carbonyl or aryl thiocarbonyl compound. The superacid is present in an amount of at most 8 equivalents in proportion to the N-(nitroaryl)-amide or N-(nitroaryl)-thioamide. A method of preparing aryl amide or aryl thioamide, comprises reacting an N-(nitroaryl)-carbamide or N-(nitroaryl)-thiocarbamide with an aromatic ring, with a superacid catalyst, to produce the aryl amide or aryl thioamide.

Подробнее
10-10-2013 дата публикации

Hepatitis C Virus Inhibitors

Номер: US20130267713A1
Принадлежит:

Hepatitis C virus inhibitors are disclosed having the general formula: This Divisional application claims the benefit of U.S. Ser. No. 13/597,381 filed Aug. 29, 2012, now allowed, which in turn is a continuation application which claims the benefit of U.S. Ser. No. 12/966,175 filed Dec. 13, 2010, now U.S. Pat. No. 8,299,094, which in turn is a continuation application which claims the benefit of U.S. Ser. No. 12/202,603 filed Sep. 2, 2008, now U.S. Pat. No. 7,915,291, which in turn is a continuation application which claims the benefit of U.S. Ser. No. 11/295,914, filed Dec. 7, 2005, now U.S. Pat. No. 7,449,479, which in turn is a continuation application which claims the benefit of U.S. Ser. No. 10/441,657, filed May 20, 2003, now U.S. Pat. No. 6,995,174, which in turn claims the benefit of provisional application U.S. Ser. No. 60/382,055, filed May 20, 2002, now expired.The present invention is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the functioning of the NS3 protease encoded by Hepatitis C virus (HCV), compositions comprising such compounds and methods for inhibiting the functioning of the NS3 protease.HCV is a major human pathogen, infecting an estimated 170 million persons worldwide—roughly five times the number infected by human immunodeficiency virus type 1. A substantial fraction of these HCV infected individuals develop serious progressive liver disease, including cirrhosis and hepatocellular carcinoma. (Lauer, G. M.; Walker, B. D. . (2001), 345, 41-52).Presently, the most effective HCV therapy employs a combination of alpha-interferon and ribavirin, leading to sustained efficacy in 40% of patients. (Poynard, T. et al. (1998), 352, 1426-1432). Recent clinical results demonstrate that pegylated alpha-interferon is superior to unmodified alpha-interferon as monotherapy (Zeuzem, S. et al. . (2000), 343, 1666-1672). However, even with experimental therapeutic regimens involving combinations of ...

Подробнее
17-10-2013 дата публикации

NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE

Номер: US20130274269A1
Принадлежит: D. Western Therapeutics Institute, Inc.

The present invention provides a novel isoquinoline-6-sulfonamide derivative that is useful as a medicine. The present invention provides an isoquinoline-6-sulfonamide derivative represented by Formula (1), a salt thereof, or a solvate of the derivative or the salt, wherein Rand Reach independently represent a hydrogen atom, or the like; Rand Reach independently represent a hydrogen atom, an alkyl group, or the like; Rrepresents a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, an optionally substituted alkanoyl group, or the like; and A represents a linear or branched alkylene group having 2 to 6 carbon atoms. 2. The compound according to claim 1 , wherein Rand Rare each independently a hydrogen atom claim 1 , a halogen atom claim 1 , a Calkyl group claim 1 , a nitro group claim 1 , a cyano group claim 1 , a halogeno Calkyl group claim 1 , a phenyl group claim 1 , a Calkenyl group claim 1 , a Calkynyl group claim 1 , a hydroxyl group claim 1 , an amino group claim 1 , an amino Calkylthio group claim 1 , or a thienyl group.3. The compound according to claim 1 , wherein a substituent on the alkyl group claim 1 , the alkenyl group claim 1 , the alkynyl group claim 1 , the cycloalkyl group claim 1 , or the alkanoyl group in Ris at least one substituent selected from the group consisting of (a) an aryl group claim 1 , a heteroaryl group claim 1 , or an arylene group optionally having claim 1 , on the ring claim 1 , at least one substituent selected from the group consisting of a halogen atom claim 1 , a cyano group claim 1 , a Calkyl group claim 1 , a halogeno Calkyl group claim 1 , a Calkenyl group claim 1 , a Calkynyl group claim 1 , a Calkoxy group claim 1 , a Calkylthio group claim 1 , a hydroxyl group claim 1 , an oxo group claim 1 , a formyl group claim 1 , a Calkanoyl group claim 1 , a carboxyl group claim 1 , a Calkyloxycarbonyl ...

Подробнее
17-10-2013 дата публикации

COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS

Номер: US20130274285A1
Принадлежит:

The present disclosure is directed to compounds and methods for treating irritable bowel syndrome, chronic kidney disease and end stage renal disease by administering to a subject in need thereof a compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure 5. The method of claim 1 , wherein the subject is human.10. The method of claim 6 , wherein the subject is human.15. The method of claim 11 , wherein the subject is human. This application is a divisional application of U.S. patent application Ser. No. 13/172,394, filed Dec. 30, 2009, allowed, which is a continuation of International PCT Patent Application No. PCT/US2009/069852, which was filed on Dec. 30, 2009, now pending, which claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 61/141,853, filed Dec. 31, 2008, U.S. Provisional Patent Application No. 61/169,509, filed Apr. 15, 2009, and U.S. Provisional Patent Application No. 61/237,842, filed Aug. 28, 2009, which applications are incorporated herein by reference in their entireties.1. FieldThe present disclosure is directed to compounds that are substantially active in the gastrointestinal tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions, and the use of such compounds in the treatment of disorders associated with fluid retention or salt overload and in the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with a gastrointestinal tract disorder.2. Description of the Related ArtDisorders Associated with Fluid Retention and Salt OverloadAccording to the American Heart Association, more than 5 million Americans have suffered from heart failure, and an estimated 550,000 cases of congestive heart failure (CHF) occur each year (Schocken, D. D. et al., ; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group: Circulation, v. 117 ...

Подробнее
17-10-2013 дата публикации

PHENYL-TETRAHYDROISOQUINOLINE DERIVATIVES

Номер: US20130274287A1
Принадлежит: Hoffmann-La Roche Inc.

The invention provides novel compounds having the general formula (I) 3. A compound according to claim 1 , wherein R claim 1 , R claim 1 , Rand Rare independently selected from H claim 1 , halogen claim 1 , cyano claim 1 , alkyl and haloalkyl.4. A compound according to claim 1 , wherein Ris H or halogen.5. A compound according to claim 1 , wherein Ris H claim 1 , alkyl or halogen.6. A compound according to claim 1 , wherein Ris H or halogen.7. A compound according to claim 1 , wherein Ris halogen claim 1 , cyano or haloalkyl.8. A compound according to claim 1 , wherein Ris cyano or haloalkyl.9. A compound according to claim 1 , wherein Ris haloalkyl.10. A compound according to claim 1 , wherein Ris H or halogen.11. A compound according to claim 1 , wherein Ris H.12. A compound according to claim 1 , wherein Ris H.13. A compound according to claim 1 , wherein Ris H or aryl substituted with R claim 1 , Rand R.14. A compound according to claim 1 , wherein Ris H.15. A compound according to claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , Rand Rare independently selected from H and alkyl.16. A compound according to claim 1 , wherein Ris H or alkyl.17. A compound according to claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , Rand Rare H.18. A compound according to claim 1 , wherein A is —(CRR)—NRR.19. A compound according to claim 1 , wherein A is —(CRR) claim 1 , —OR.20. A compound according to claim 1 , wherein Ris H.21. A compound according to claim 1 , wherein Ris H claim 1 , alky claim 1 , —S(O)R claim 1 , —S(O)NRR claim 1 , —C(O)R claim 1 , —C(O)ORor —C(O)NRR.22. A compound according to claim 1 , wherein in case A is{'sup': 13', '14', '15', '16', '16', '17', '17', '18', '17', '17', '17', '18, 'sub': p', '2', '2, '—(CRR)—NRR, then Ris H, —S(O)R, —S(O)NRR, —C(O)R, —C(O)ORor —C(O)NRR.'}23. A compound according to claim 1 , wherein in case A is{'sup': 13', '14', '16', '16', '17', '18, 'sub': 'p', '—(CRR)—OR, then Ris H, alkyl or —C(O)NRR.'}24. A ...

Подробнее
17-10-2013 дата публикации

Monocyclic cyanoenones and methods of use thereof

Номер: US20130274480A1
Принадлежит: Dartmouth College

The present invention features monocyclic cyanoenone compositions and methods for using the same in the treatment of diseases such as cancer, inflammatory diseases and neurodegenerative diseases.

Подробнее
24-10-2013 дата публикации

Treatment of diseases by epigenetic regulation

Номер: US20130281398A1
Принадлежит: RVX Therapeutics Inc

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

Подробнее
24-10-2013 дата публикации

PALLADIUM CATALYST, METHOD FOR ITS PREPARATION AND ITS USE

Номер: US20130281700A1
Принадлежит:

The invention relates to palladium(0)-tris{tri-[3,5-bis(trifluoromethyl)-phenyl]-phosphine} complex of formula (I), as well as to its preparation and use. 2. The composition of in a solid form.3. The composition of having a melting point of 220° C. as determined by DSC in inert atmosphere.4. The composition of claim 1 , having a decomposition point of 169.5° C. as determined by DSC in air under atmospheric pressure.5. A palladium(0) complex comprising three fluorinated phosphine compounds.6. The palladium(0) complex of exhibiting a stability characterized by no measurable decomposition on the basis of P claim 5 , F claim 5 , C and H NMR spectra following 4 months of storage in air at a temperature of 25° C.7. The palladium(0) complex of exhibiting a stability characterized by no measurable decomposition on the basis of P claim 5 , F claim 5 , C and H NMR spectra following 20 months of storage in air at room temperature.8. The palladium(0) complex of having a melting point in inert atmosphere of 220° C.9. The palladium(0) complex of exhibiting stability at any temperature below its melting point.10. The palladium(0) complex of exhibiting insolubility in water at industrially relevant temperatures and stability when stored in water.11. The palladium(0) complex of comprising a yellow solid.12. The palladium(0) complex of that dissolves at around 90° C. in aqueous alcohols.13. The palladium(0) complex of having catalytic activity in cross coupling reactions at a concentration of from 0.1 to 0.3 mole % of the substrate.14. A method for catalysing a C—C claim 5 , C-heteroatom claim 5 , or hydrogenation reaction comprising carrying out the C—C claim 5 , C-heteroatom or hydrogenation reaction in the presence of the palladium(0) complex of .15. The method of claim 14 , wherein the reaction is a C—C cross-coupling reaction.16. The method of claim 14 , wherein the C—C cross-coupling reaction is selected from the group consisting of: Suzuki coupling claim 14 , Heck coupling and ...

Подробнее
31-10-2013 дата публикации

Isoquinoline Compounds And Methods For Treating HIV

Номер: US20130289027A1
Принадлежит: ViiV Healthcare UK Limited

Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the retrovirus family of viruses such as the Human Immunodeficiency Virus (HIV). 134-. (canceled)3638-. (canceled)39. A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of a compound or salt as defined in .40. A method for treating a viral infection in a mammal mediated at least in part by a virus in the retrovirus family of viruses which method comprises administering to a mammal claim 35 , that has been diagnosed with said viral infection or is at risk of developing said viral infection claim 35 , a compound or salt as defined in .41. The method of claim 40 , wherein said virus is an HIV virus.42. The method according to claim 40 , further comprising administration of a therapeutically effective amount of one or more agents active against an HIV virus.43. The method according to claim 42 , wherein said agent active against HIV virus is selected from Nucleotide reverse transcriptase inhibitors; Non-nucleotide reverse transcriptase inhibitors; Protease inhibitors; Entry claim 42 , attachment and fusion inhibitors; Integrase inhibitors; Maturation inhibitors; CXCR4 inhibitors; and CCR5 inhibitors. This is a Patent Cooperation Treaty application and claims the benefit of U.S. Provisional Application No. 61/435,783, filed Jan. 24, 2011 and U.S. Provisional Application No. 61/510,534, filed Jul. 22, 2011, both of which are hereby incorporated by reference in their entireties.The present invention relates to substituted isoquinoline compounds, pharmaceutical compositions, and methods of use thereof for (i) inhibiting HIV replication in a subject infected with HIV, or (ii) treating a subject infected with HIV, by administering such compounds.Presently, long-term suppression of viral replication with ...

Подробнее
31-10-2013 дата публикации

NOVEL PHARMACEUTICAL FORMS, AND METHODS OF MAKING AND USING THE SAME

Номер: US20130289280A1
Принадлежит:

Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided. 1. A bicalutamide , donepezil , nelfinavir , or tamsulosin salt made by reacting bicalutamide , donepezil , nelfinavir , or tamsulosin with an organic or inorganic acid in a crystallization solvent , wherein the form has an aqueous solubility of approximately 5 micrograms/mL to approximately 100 mg/mL.2. The bicalutamide claim 1 , donepezil claim 1 , nelfinavir claim 1 , or tamsulosin salt of claim 1 , comprising an (R)-tamsulosin HCl salt that is crystallized in a crystallization solvent comprising methanol.3. The bicalutamide claim 1 , donepezil claim 1 , nelfinavir claim 1 , or tamsulosin salt of claim 1 , comprising a nelfinavir HCl salt that is crystallized in a crystallization solvent comprising propylene glycol.4. The bicalutamide claim 1 , donepezil claim 1 , nelfinavir claim 1 , or tamsulosin salt of claim 1 , wherein the mole ratio of bicalutamide claim 1 , donepezil claim 1 , nelfinavir claim 1 , tamsulosin claim 1 , or a derivative thereof to the salt forming component is about M:N claim 1 , wherein M is an integer from 1 to 100 and N is an integer from 1 to 100.5. The bicalutamide claim 4 , donepezil claim 4 , nelfinavir claim 4 , or tamsulosin salt of claim 4 , wherein M is an integer from 1 to 20 and N is an integer from 1 to 20.6. The bicalutamide claim 1 , donepezil claim 1 , nelfinavir claim 1 , or tamsulosin salt of claim 1 , wherein the salt is crystalline.7. The bicalutamide claim 1 , donepezil claim 1 , nelfinavir claim 1 , or tamsulosin salt of claim 1 , wherein said tamsulosin salt is a (R)-tamsulosin salt comprising (R)-tamsulosin HCl.8. The (R)-tamsulosin salt of claim 7 , wherein: {'sup': '3', 'Monoclinic, P2(1), a=7.5499(13) Å, b=9.1496(15) Å, c=31.755(5) Å, ...

Подробнее
14-11-2013 дата публикации

INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1

Номер: US20130303522A1
Принадлежит: LABORATORIOS SALVAT, S.A.

The compounds of formula (I) are derived from perhydroquinoline and perhydroisoquinoline and are useful as active pharmaceutical ingredients for the prophylaxis or treatment of diseases caused by 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD1) enzyme-associated disorders, such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, Cushing's syndrome, psoriasis, rheumatoid arthritis, cognitive disorders, Alzheimer's disease or neurodegeneration. 2. The method according to claim 1 , wherein in the compound Y is CO or SO.3. The method according to claim 1 , wherein in the compound W1 and W2 is each independently selected from the group consisting of a bond claim 1 , S and NR1.4. The method according to claim 3 , wherein in the compound R1 is H5. The method according to claim 1 , wherein in the compound V is —CO-T claim 1 , —CS-T or —SO-T.7. The method according to claim 1 , wherein in the compound T is NR2R3 claim 1 , R2 claim 1 , OR2 or SR2.8. The method according to claim 1 , wherein in the compound R2 and R3 is each independently selected from the group consisting of H claim 1 , COR4 claim 1 , SOR4 claim 1 , Calkyl claim 1 , phenyl claim 1 , naphthyl claim 1 , benzyl claim 1 , phenethyl claim 1 , Calkenyl claim 1 , Ccycloalkyl claim 1 , and heterocycle claim 1 , particularly claim 1 , 2-furanyl claim 1 , 2-thiophenyl claim 1 , 2-(1-methylindole) claim 1 , quinoline claim 1 , isoquinoline and 2-benzofuranyl.9. The method according to claim 8 , wherein in the compound R2 and R3 is each independently selected from the groups consisting of Calkyl and Calkenyl.10. The method according to claim 9 , wherein in the compound R2 or R3 are optionally substituted with one or several substituents independently selected from the groups consisting of F claim 9 , OR4 claim 9 , NR4R5 claim 9 , COOR4 claim 9 , CONR4R5 claim 9 , phenyl claim 9 , Ccycloalkyl claim 9 , hexenyl claim 9 , ...

Подробнее
21-11-2013 дата публикации

Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions

Номер: US20130310555A1
Автор: Hyun-Soon Chong
Принадлежит: Illinois Institute of Technology

Stereoselective and regioselective synthesis of compounds via nucleophilic ring opening reactions of aziridinium ions for use in stereoselective and regioselective synthesis of therapeutic and diagnostic compounds.

Подробнее
21-11-2013 дата публикации

ISOPRENYL COMPOUNDS AND METHODS THEREOF

Номер: US20130310559A1
Принадлежит: SIGNUM BIOSCIENCES, INC.

Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses. 2. (canceled)3. The compound according to claim 1 , wherein L is selected from a bivalent claim 1 , branched or unbranched claim 1 , saturated or unsaturated claim 1 , Chydrocarbon chain wherein one or more methylene units of L is independently replaced by —NH— claim 1 , —C(O)— claim 1 , —CH═CH— claim 1 , C-Ccycloalkylene claim 1 , C-Cheterocycloalkylene claim 1 , 8-10-membered bicyclic heterocyclic moiety claim 1 , an optionally substituted arylene and optionally substituted heteroarylene claim 1 , and wherein L is optionally substituted by one or more groups selected from halogen claim 1 , substituted or unsubstituted C-Calkyl claim 1 , and —NHC(O)CH.5. The compound according to claim 1 , wherein L is selected from a bivalent claim 1 , branched or unbranched claim 1 , saturated or unsaturated claim 1 , Chydrocarbon chain wherein one or more methylene units of L is independently replaced by —NH— claim 1 , —C(O)— claim 1 , —C(═CH)— claim 1 , —CH═CH— claim 1 , C-Ccycloalkylene claim 1 , 8-10-membered bicyclic heterocyclic moiety claim 1 , an optionally substituted arylene and optionally substituted heteroarylene claim 1 , and wherein L is optionally ...

Подробнее
21-11-2013 дата публикации

NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Номер: US20130310565A1
Принадлежит:

The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. 141-. (canceled) This application is a continuation of U.S. application Ser. No. 13/599,161, filed Aug. 30, 2012, which application is a continuation of U.S. application Ser. No. 13/186,351, filed Jul. 19, 2011, now U.S. Pat. No. 8,278,325, which application is a continuation application of U.S. application Ser. No. 12/015,275, filed Jan. 16, 2008, now U.S. Pat. No. 8,017,625, which application is a divisional application of U.S. application Ser. No. 10/861,082, filed Jun. 4, 2004, now U.S. Pat. No. 7,323,475, which claims the benefit under 35 U.S.C. §119(e) of U.S. Application Nos. 60/476,811, filed Jun. 6, 2003, 60/476,420 filed, Jun. 6, 2003, 60/476,633, filed Jun. 6, 2003, and 60/476,519, filed Jun. 6, 2003, all of which are hereby incorporated by reference in their entirety.1. Field of the InventionThe present invention relates to methods and compounds capable of modulating the stability of the alpha subunit of hypoxia inducible factor (HIF) and increasing endogenous erythropoietin, ex vivo and in vivo.2. State of the ArtAn early response to tissue hypoxia is induction of hypoxia inducible factor (HIF), a basic helix-loop-helix (bHLH) PAS (Per/Arnt/Sim) transcriptional activator that mediates changes in gene expression in response to changes in cellular oxygen concentration. HIF is a heterodimer containing an oxygen-regulated alpha subunit (HIFα) and a constitutively expressed beta subunit (HIFβ), also known as aryl hydrocarbon receptor nuclear transporter (ARNT). In oxygenated (normoxic) cells, HIFα subunits are rapidly degraded by a mechanism that involves ubiquitination by the von Hippel-Lindau tumor suppressor (pVHL) E3 ligase complex. Under hypoxic conditions, HIFα is not degraded, and an active HIFα/β complex accumulates in the nucleus and ...

Подробнее
28-11-2013 дата публикации

TETRAHYDROISOQUINOLINE DERIVATIVE

Номер: US20130317010A1
Принадлежит: Astellas Pharma Inc

To provide an excellent agent for preventing or treating dementia and schizophrenia based on serotonin 5-HTreceptor regulating action, it was found that a tetrahydroisoquinoline derivative characterized by a structure in which an acylguanidino group binds to a N atom of a tetrahydroisoquinoline ring or the like, and a cyclic group binds to an unsaturated ring has a potent 5-HTreceptor regulating action and an excellent pharmacological action based on the regulating action and also discovered that the tetrahydroisoquinoline derivative is useful as an agent for treating or preventing dementia, schizophrenia, and the like, whereby the present invention has been completed. 2. The compound according to or a pharmaceutically acceptable salt thereof claim 1 ,{'sup': 1', '1', '2', '3', '4, 'wherein Rrepresents phenyl, pyridyl, or cycloalkyl which may be respectively substituted with group(s) selected from G, Rrepresents halogen, m represent 1, n represents 1, and both Rand Rrepresent H.'}3. The compound according to or a pharmaceutically acceptable salt thereof claim 1 ,{'sup': 1', '2', '3', '4, 'wherein Rrepresents phenyl which may be substituted with halogen or —O-(lower alkyl), Rrepresents H, F, Cl, or methyl, m represents 1, n represents 1, and both Rand Rrepresent H.'}4. The compound according to or a pharmaceutically acceptable salt thereof claim 1 ,{'sup': 1', '2', '3', '4, 'wherein Rrepresents pyridyl which may be substituted with halogen or —O-(lower alkyl), Rrepresents H, F, Cl, or methyl, m represents 1, n represents 1, and both Rand Rrepresent H.'}5. The compound according to or a pharmaceutically acceptable salt thereof claim 1 ,{'sup': 1', '2', '3', '4, 'wherein Rrepresents phenyl which may be substituted with halogen or —O-(lower alkyl), Rrepresents H, F, Cl, or methyl, m represents 1, n represents 1, and Rand Rform cyclopropane-1,1-diyl or cyclobutane-1,1-diyl together with the carbon atom binding thereto, as ethylene or trimethylene.'}6. A compound selected ...

Подробнее
05-12-2013 дата публикации

Indanyloxyphenylcyclopropanecarboxylic acids

Номер: US20130324514A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to compounds of general formula I, wherein the groups R 1 , R 2 , R 3 , m and n are defined as in claim 1 , which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

Подробнее
05-12-2013 дата публикации

PROCESSES AND REAGENTS FOR MAKING DIARYLIODONIUM SALTS

Номер: US20130324718A1
Автор: DiMagno Stephen
Принадлежит:

This invention relates to processes and reagents for making diaryliodonium salts, which are useful for the preparation of fluorinated and radiofluorinated aromatic compounds. 2. The process of claim 1 , wherein the process is carried out in the absence of added acid.3. The process of claim 1 , wherein the process utilizes (1-chloromethyl-4-fluoro-1 claim 1 ,4-diazoniabicyclo[2.2.2]octane)bis(tetrafluoroborate).4. The process of claim 1 , wherein the process utilizes (1-fluoro-4-methyl-1 claim 1 ,4-diazoniabicyclo[2.2.2]octane)bis(tetrafluoroborate).5. The process of claim 1 , wherein the process utilizes N-fluoro-2 claim 1 ,3 claim 1 ,4 claim 1 ,5 claim 1 ,6-pentachloropyridinium tetrafluoroborate.6. The process of claim 1 , wherein the process utilizes less than 2 equivalents of (1-chloromethyl-4-fluoro-1 claim 1 ,4-diazoniabicyclo[2.2.2]octane)bis(tetrafluoroborate) claim 1 , (1-fluoro-4-methyl-1 claim 1 ,4-diazoniabicyclo[2.2.2]octane)bis(tetrafluoroborate) claim 1 , or optionally substituted N-fluoropyridinium tetrafluoroborate for 1 equivalent of the compound of Formula II.7. The process of claim 1 , wherein the process utilizes less than 1.5 equivalents of (1-chloromethyl-4-fluoro-1 claim 1 ,4-diazoniabicyclo[2.2.2]octane)bis(tetrafluoroborate) claim 1 , (1-fluoro-4-methyl-1 claim 1 ,4-diazoniabicyclo[2.2.2]octane)bis(tetrafluoroborate) claim 1 , or optionally substituted N-fluoropyridinium tetrafluoroborate for 1 equivalent of the compound of Formula II.8. The process of claim 1 , wherein each X is claim 1 , independently claim 1 , a ligand that is a conjugate base of an acid HX claim 1 , wherein HX has a pKa of less than or equal to 5.9. The process of claim 1 , wherein each X is O(C═O)CH.10. The process of claim 1 , wherein the tetravalent silicon moiety is (R)Si—X claim 1 , wherein each Ris claim 1 , independently claim 1 , Calkyl or aryl.11. The process of claim 10 , wherein each Ris methyl.12. The process of claim 10 , wherein (R)Si—X is (CH)Si—X.13. The ...

Подробнее
19-12-2013 дата публикации

Novel 1-(1-OXO-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL)Urea Derivatives As N-FORMYL Peptide Receptor Like-1 (FPRL-1) Receptor Modulators

Номер: US20130338187A1
Принадлежит:

The present invention relates to novel 1-(1-Oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor. 2. The method according to claim 1 , wherein the mammal is a human.11. The method according to claim 1 , wherein the compound is selected from:1-(4-acetylphenyl)-3-[2-(3-aminopropyl)-3-(4-cyanophenyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl]urea;1-(4-acetylphenyl)-3-[2-(2-aminoethyl)-3-(4-cyanophenyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl]urea;1-(4-acetylphenyl)-3-{3-(4-cyanophenyl)-2-[2-(1H-imidazol-4-yl)ethyl]-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl}urea;1-(4-acetylphenyl)-3-{3-(4-cyanophenyl)-2-[2-(methylamino)ethyl]-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl}urea;1-[2-(3-aminopropyl)-3-(4-cyanophenyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl]-3-[4-(trifluoromethyl)phenyl]urea;1-{3-(4-cyanophenyl)-2-[2-(1H-imidazol-4-yl)ethyl]-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl}-3-[4-(trifluoromethyl)phenyl]urea;1-[2-(3-aminopropyl)-3-(4-cyanophenyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl]-3-[4-(methylthio)phenyl]urea;1-(4-acetylphenyl)-3-{3-(3,4-dichlorophenyl)-2-[2-(1H-imidazol-4-yl)ethyl]-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl}urea;1-[2-(3-aminopropyl)-3-(4-cyanophenyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl]-3-(4-bromophenyl)urea;1-[2-(3-aminopropyl)-3-(4-cyanophenyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl]-3-[4-(methylsulfinyl)phenyl]urea;1-[2-(3-aminopropyl)-3-(4-cyanophenyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl]-3-[4-(methylsulfonyl)phenyl]urea;1-{3-(4-cyanophenyl)-2-[2-(1H-imidazol-4-yl)ethyl]-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl}-3-[4-(methylthio)phenyl]urea;1-{3-(4-cyanophenyl)-2-[2-(1H-imidazol-4-yl)ethyl]-1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl}-3-[4-(methylsulfinyl)phenyl]urea;1-{3-(4-cyanophenyl)-2-[2-(1H-imidazol-4-yl)ethyl]-1-oxo-1,2,3,4-tetrahydroisoquinolin-7- ...

Подробнее
02-01-2014 дата публикации

NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND

Номер: US20140005382A1
Принадлежит: TAISHO PHARMACEUTICAL CO., LTD.

There are provided compounds represented by the following general formula (I) or pharmaceutically acceptable salts of thereof, which have a superior monoacylglycerol acyltransferase 2 inhibitory action: 3. The compound of the general formula (I) above or pharmaceutically acceptable salt thereof according to claim 1 , wherein Ris the formula (II).4. The compound of the general formula (I) above or pharmaceutically acceptable salt thereof according to claim 1 , wherein{'sup': 'B', 'Ris the formula (II),'}{'sup': 11', '12', '11', '12', '11', '12, 'sub': 1-4', '3-6, 'V is the formula —CRR—, wherein Rand R, which may be the same or different, each represent a hydrogen atom or a Calkyl group, or Rand R, taken together with the adjacent carbon atom, may form Ccycloalkane,'}m is 1, andn is 0.5. The compound of the general formula (I) above or pharmaceutically acceptable salt thereof according to claim 3 , wherein{'sup': 11', '12', '11', '12, 'sub': '1-4', 'V is the formula —CRR—, wherein Rand R, which may be the same or different, each represent a hydrogen atom or a Calkyl group,'}m is 1, andn is 0.6. The compound of the general formula (I) above or pharmaceutically acceptable salt thereof according to claim 3 , whereinV is the formula —CO—NH—,W is a single bond,m is 1, andn is 0.7. The compound of the general formula (I) above or pharmaceutically acceptable salt thereof according to claim 3 , whereinV is the formula —CO—NH—,W is a single bond,m is 0, andn is 0.8. The compound of the general formula (I) above or pharmaceutically acceptable salt thereof according to claim 1 , wherein Ring A is an aryl group which may be substituted by 1 to 3 substituents claim 1 , which may be the same or different claim 1 , selected from the group consisting of (i) to (vii) below:(i) a halogen atom,(ii) a hydroxy group,{'sub': '1-8', '(iii) a Calkyl group which may be substituted by 1 to 3 substituents, which may be the same or different, selected from the group consisting ofa hydroxy group ...

Подробнее
02-01-2014 дата публикации

Sulfonamide compounds having trpm8 antagonistic activity

Номер: US20140005393A1
Принадлежит: Mitsubishi Tanabe Pharma Corp

Sulfonamide compounds having TRPM8 antagonistic activity are provided. A sulfonamide compound of formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof: (I) wherein Ring A is bicyclic aromatic heterocycle comprised of (a) pyridine is condensed with benzene; or (b) pyridine is condensed with monocyclic aromatic heterocycle, and Ring A binds to a sulfonylamino moiety on a carbon atom adjacent to a nitrogen atom of the pyridine ring constituting Ring A, Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; (b) monocyclic or bicyclic alicyclic hydrocarbon; (c) monocyclic or bicyclic aromatic heterocycle; or (d) monocyclic or bicyclic non-aromatic heterocycle, Ring C is (a) benzene; or (b) monocyclic aromatic heterocycle, and other symbols are the same as defined in the specification.

Подробнее
09-01-2014 дата публикации

New palladium catalyst, method for its preparation and its use

Номер: US20140012004A1
Принадлежит: H4SEP KFT

The invention relates to palladium(0) tris{tri-[3,5-bis(trifluoromethyl)-phenyl]-phosphine} complex of formula (I), as well as to its preparation and use. This compound is outstandingly stable, and can be used as catalyst with excellent results.

Подробнее
23-01-2014 дата публикации

CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR

Номер: US20140024675A1
Принадлежит:

The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof. 1. Crystalline [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid (Compound A Form A) characterized by an X-ray powder diffractogram comprising the following peaks: 8.5 , 16.2 , and 27.4 °2θ±0.2 °2θ.2. Compound A Form A according to claim 1 , wherein the diffractogram further comprises peaks at 12.8 claim 1 , 21.6 claim 1 , and 22.9 °2θ±0.2 °2θ.3. Compound A Form A according to claim 1 , wherein the diffractogram is substantially as shown in .4. Compound A Form A according to claim 1 , characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 223° C.5. Compound A Form A according to claim 4 , wherein the DSC curve is substantially as shown in .6. Crystalline [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid hemihydrate (Compound A Form B) characterized by an X-ray powder diffiractogram comprising the following peaks: 4.2 claim 4 , 8.3 claim 4 , and 16.6 °2θ±0.2 °2θ.7. Compound A Form B according to claim 6 , wherein the diffractogram further comprises peaks at 12.5 claim 6 , 14.1 claim 6 , and 17.4 °2θ±0.2 °2θ.8. Compound A Form B according to claim 6 , wherein the diffractogram is substantially as shown in .9. Compound A Form B according to claim 6 , characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 222° C.10. Compound A Form B according to claim 9 , wherein the DSC curve is substantially as shown in .11. Crystalline [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid hexafluoropropan-2-ol solvate (Compound A Form C) characterized by an X-ray powder diffractogram comprising the following peaks: 4.5 claim 9 , 13.7 claim 9 , and 16.4 °2θ±0.2 °2θ.12. Compound A Form C ...

Подробнее
23-01-2014 дата публикации

CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR

Номер: US20140024676A1
Принадлежит:

The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof. 154-. (canceled)55. A pharmaceutical composition comprising crystalline [4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid (Compound A Form A) characterized by an X-ray powder diffractogram comprising the following peaks: 8.5 , 16.2 , and 27.4°2θ±0.2°2θ , and a pharmaceutically acceptable excipient , wherein at least about 85% of Compound A is in Form A.5657-. (canceled)58. The pharmaceutical composition of claim 55 , wherein at least about 90% of Compound A is in Form A.59. The pharmaceutical composition of claim 55 , wherein at least about 95% of Compound A is in Form A.60. The pharmaceutical composition of claim 55 , wherein at least about 99% of Compound A is in Form A.61. The pharmaceutical composition of claim 55 , wherein at least about 99.5% of Compound A is in Form A.62. The pharmaceutical composition of claim 55 , wherein at least about 99.9% of Compound A is in Form A.63. The pharmaceutical composition of claim 55 , wherein at least about 99.99% of Compound A is in Form A.64. A method for treating claim 55 , pretreating claim 55 , or delaying onset or progression of a condition mediated at least in part by hypoxia inducible factor (HIF) claim 55 , comprising administering to a patient in need thereof claim 55 , a therapeutically effective amount of the pharmaceutical composition of .65. The method of claim 64 , wherein the condition mediated at least in part by HIF is tissue damage associated with ischemia or hypoxia.66. The method of claim 65 , wherein the ischemia is associated with an acute event selected from the group consisting of myocardial infarction claim 65 , pulmonary embolism claim 65 , intestinal infarction claim 65 , chronic kidney failure claim 65 , ischemic stroke claim 65 , and renal ...

Подробнее
06-02-2014 дата публикации

3-UREIDOISOQUINOLIN-8-YL DERIVATIVES

Номер: US20140038961A1
Принадлежит: ACTELION PHARMACEUTICALS LTD.

The invention relates to 3-ureidoisoquinolin-8-yl derivatives of formula I 2. The compound according to claim 1 ,{'sup': x', 'z', 'y, 'wherein each of Rand Ris H and Ris methoxy, or hydroxymethyl;'}or a salt thereof.5. The compound according to claim 1 , wherein Ris (C-C)alkyl;or a salt thereof.6. The compound according to claim 5 , wherein Ris ethyl;or a salt thereof.7. The compound according to claim 1 , wherein Ris H;or a salt thereof.8. The compound according to claim 7 , wherein Ris (C-C)alkyl and Ris (C-C)alkynyl claim 7 , linear (C-C)alkynyloxy claim 7 , (C-C)cycloalkyl claim 7 , (C-C)cycloalkyl-(C-C)alkyl claim 7 , aryl claim 7 , (C-C)heteroaryl claim 7 , ((C-C)heteroaryl)methoxy or benzyl;or a salt thereof.10. The compound according to claim 9 , wherein Ris pyridin-4-yl;or a salt thereof.11. The compound according to claim 9 , wherein Ris alkynyloxy claim 9 , (C-C)heteroaryl or ((C-C)heteroaryl)methoxy;or a salt thereof.12. The compound according to claim 1 , wherein the compound is:but-3-ynoic acid [3-(3-ethyl-ureido)-isoquinolin-8-ylmethyl]-amide;N-[3-(3-ethyl-ureido)-isoquinolin-8-ylmethyl]-isonicotinamide;N-[3-(3-ethyl-ureido)-isoquinolin-8-ylmethyl]-acetamide;N-[3-(3-ethyl-ureido)-isoquinolin-8-ylmethyl]-benzamide;2-cyano-N-[3-(3-ethyl-ureido)-isoquinolin-8-ylmethyl]-acetamide;cyclohexanecarboxylic acid [3-(3-ethyl-ureido)-isoquinolin-8-ylmethyl]-amide;2-cyclopropyl-N-[3-(3-ethyl-ureido)-isoquinolin-8-ylmethyl]-acetamide;2-acetylamino-N-[3-(3-ethyl-ureido)-isoquinolin-8-ylmethyl]-acetamide;propynoic acid [3-(3-ethyl-ureido)-isoquinolin-8-ylmethyl]-amide;N-[3-(3-ethyl-ureido)-isoquinolin-8-ylmethyl]-nicotinamide;pyridine-2-carboxylic acid [3-(3-ethyl-ureido)-isoquinolin-8-ylmethyl]-amide;N-[3-(3-ethyl-ureido)-isoquinolin-8-ylmethyl]-2-phenyl-acetamide;cyclopropanecarboxylic acid [3-(3-ethyl-ureido)-isoquinolin-8-ylmethyl]-amide;N-[3-(3-ethyl-ureido)-isoquinolin-8-ylmethyl]-2,2-dimethyl-propionamide;N-[3-(3-ethyl-ureido)-isoquinolin-8-ylmethyl]-2-methoxy ...

Подробнее
06-02-2014 дата публикации

METHOD FOR PRODUCING N-SUBSTITUTED AMINE COMPOUNDS THROUGH CATALYZED ALKYLATION

Номер: US20140039181A1

The invention relates to a method for producing a N-substituted amine compound by catalyzed alkylation. The method uses amine and alcohol or two kinds of amines as the reaction materials, employs composite metal oxides catalyst at a reaction temperature of 80-180° C. to catalyze the reaction for 6-36 hours, so as to produce the N-substituted amine compound. The reaction condition of the method of the invention is relatively moderate, using a catalyst made of cheap non-noble metals, which is non-caustic and easy to be separated and reused. The reaction does not need any medium and has relatively high conversion rate and selectivity. 2. The method of claim 1 , wherein the molar ratio of Cu to Ni is from 10:1 to 1:10 claim 1 , and the molar ratio of Cu to Fe is from 10:1 to 1:10 in CuO—NiO—FeO.3. The method of claim 1 , wherein the molar ratio of Ni to Fe in NiO—FeOis from 10:1 to 1:10.4. The method of claim 1 , wherein the molar ratio of Cu to Fe in CuO—FeOis from 10:1 to 1:10.5. The method of claim 1 , wherein the molar ratio of Cu to Ni in CuO—NiO is from 10:1 to 1:10.6. (canceled)7. The method of claim 1 , wherein the mass ratio between the composite metal oxide catalyst and the amine is from 0.01:1 to 1.2:1.8. The method of claim 1 , wherein the composite metal oxide catalyst is produced by the following steps:{'sub': 3', '2', '3', '2', '3', '3', '3', '3, '1) adding an aqueous solution of any two or three nitrates selected from Cu(NO), Ni(NO), and Fe(NO), and an aqueous Al(NO)solution, to an aqueous alkali metal oxide or hydroxide solution, aqueous ammonia, or aqueous carbamide solution which functions as a precipitator to coprecipitate;'}2) after step 1), providing a crude catalyst by washing, drying in the air, calcining, and reducing in hydrogen gas;{'sub': 3', '4', '3', '4', '3', '4, '3) using an aqueous alkali metal hydroxide solution to remove any alumina in the crude catalyst obtained in steps 1) and 2) to provide a composite metal oxides catalyst CuO—NiO— ...

Подробнее
13-02-2014 дата публикации

ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS

Номер: US20140045846A1
Принадлежит: NERVIANO MEDICAL SCIENCES S.R.L.

There are provided substituted isoquinolin-1(2H)-one derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of the present invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds. A screening method for the identification of compounds capable of binding several PARP proteins, as well the probes used in such method, are further objects of the invention. 2. The method of wherein the mammal in need thereof is a human.4. A compound of formula (II) as defined in . The present application is a divisional application of co-pending application having U.S. Ser. No. 13/320,969, filed on Mar. 5, 2012, which is a 371 of International Application having Serial No. PCT/EP2010/056921, filed on May 19, 2010, which claims priority of European Patent Application No. 09160869.5, filed on May 21, 2009, the contents of all of which are incorporated herein by, reference.The present invention concerns substituted isoquinolin-1(2H)-one derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.Poly (ADP-ribose) polymerases belong to a family of 17 members that catalyze the ...

Подробнее
20-02-2014 дата публикации

MODULATORS OF CELLULAR ADHESION

Номер: US20140051675A1
Принадлежит: SARcode Bioscience Inc.

The present invention provides compounds having formula (I): 175.-. (canceled)76. A pharmaceutical formulation comprising an LFA-1 antagonist or a pharmaceutically acceptable salt or ester thereof , wherein the formulation is an inhalation formulation.80. The formulation of claim 76 , wherein the compound is present in an amount effective to modulate adhesion between intracellular adhesion molecules (e.g. claim 76 , ICAM-1 claim 76 , -2 and -3) and the leukocyte integrin family of receptors.81. The formulation of claim 76 , wherein the compound is present in an amount effective to antagonize CD11/CD18 receptors associated with leukocytes.82. The formulation of claim 76 , wherein the LFA-1 antagonist is a sodium claim 76 , potassium claim 76 , lithium claim 76 , magnesium claim 76 , or calcium salt.83. The formulation of claim 76 , wherein the formulation is in the form of a powder claim 76 , solution claim 76 , spray claim 76 , or inhalant.84. The formulation of claim 76 , further comprising at least one additional therapeutic agent.85. A method for treatment of an inflammatory or immune related disorder in a subject comprising administering to said subject in need thereof an inhalation formulation comprising an LFA-1 antagonist or a pharmaceutically acceptable salt or ester thereof claim 76 , and a pharmaceutically acceptable excipient.89. The method of claim 85 , wherein the compound is present in an amount effective to modulate adhesion between intracellular adhesion molecules (e.g. claim 85 , ICAM-1 claim 85 , -2 and -3) and the leukocyte integrin family of receptors.90. The method of claim 85 , wherein the compound is present in an amount effective to antagonize CD11/CD18 receptors associated with leukocytes.91. The method of claim 85 , wherein the LFA-1 antagonist is a sodium claim 85 , potassium claim 85 , lithium claim 85 , magnesium claim 85 , or calcium salt.92. The method of claim 85 , wherein the formulation is in the form of a powder claim 85 , solution ...

Подробнее
20-02-2014 дата публикации

Modulators of atp-binding cassette transporters

Номер: US20140051724A1
Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Подробнее
27-02-2014 дата публикации

Methods For Increasing Mean Corpuscular Volume

Номер: US20140057941A1
Автор: Yu Kin-Hung (Peony)
Принадлежит:

The invention relates to methods and compounds useful for treating deficiencies in hemoglobin production. Methods and compounds useful for increasing mean corpuscular volume are provided. Methods and compounds for treating microcytosis and methods and compounds for treating microcytic anemia are also provided. 1. A method of increasing mean corpuscular volume (MCV) in a human subject , the method comprising administering the compound [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid to the subject , thereby increasing MCV.2. The method of claim 1 , wherein the subject has a lower than normal MCV.3. The method of claim 1 , wherein the subject is in need of increased MCV.4. The method of claim 1 , wherein the subject has an MCV below 80 ft.5. The method of claim 1 , wherein the MCV is increased to a value of from 80 fL to about 100 fL.6. The method of claim 1 , wherein the method does not include administration of supplemental IV iron to the subject.7. The method of claim 1 , wherein the subject has chronic kidney disease.8. The method of claim 1 , wherein the subject has stage 3 or stage 4 chronic kidney disease.9. The method of claim 1 , wherein the subject has end-stage renal disease.10. The method of claim 9 , wherein the subject is receiving stable maintenance hemodialysis. The invention relates to methods and compounds useful for treating deficiencies in hemoglobin production. Methods and compounds useful for increasing mean corpuscular volume are provided. Methods and compounds for treating microcytosis and methods and compounds for treating microcytic anemia are also provided.Effective treatment of anemia in human subjects requires a coordinated response that overcomes pathophysiological stresses antagonizing red blood cell (RBC) production to yield a sufficient population of normal RBCs that can be maintained over time. Anemia typically results from any assault on the function of the kidney or bone marrow as these organs are the ...

Подробнее
27-02-2014 дата публикации

TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF

Номер: US20140058100A1
Принадлежит: Seldar Pharma Inc.

To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS. 1. (canceled)4. The method as described in claim 3 , wherein Ris —H.5. The method as described in claim 4 , wherein Ris phenyl which may be substituted with halogen claim 4 , lower alkyl claim 4 , or —OR.6. The method as described in or a pharmaceutically acceptable salt thereof claim 5 , wherein Ris —N(R)-lower alkylene-(aryl or heteroaryl claim 5 , which may each be substituted) claim 5 , or —N(R)—O-lower alkylene-(aryl or heteroaryl claim 5 , which may each be substituted).7. The method as described in claim 6 , wherein Ris (lower alkylene)-OH or substituted cycloalkyl {wherein said lower alkylene may be substituted with a member selected from the group consisting of —OH and phenyl (which may be substituted with halogen claim 6 , lower alkyl claim 6 , or —OR claim 6 , and said substituted cycloalkyl is substituted with a member selected from the group consisting of —OR claim 6 , —N(R) claim 6 , —N(R)C(O)R claim 6 , —N(R)-lower alkylene-OR claim 6 , —N(R)S(O)-lower alkyl and heterocyclic group}.8. The method according to claim 3 , wherein the compound is (4-{[({[(3R claim 3 ,4R)-3-(2 claim 3 ,4-dichlorophenyl)-2-{(1S claim 3 ,2S)-2-[(methylsulfonyl)amino]cyclohexyl}-1-oxo-1 claim 3 ,2 claim 3 ,3 claim 3 ,4-tetrahydroisoquinolin-4-yl]carbonyl}amino)oxy]methyl}phenyl)acetic acid claim 3 , or a pharmaceutically acceptable salt thereof.10. The ...

Подробнее
06-03-2014 дата публикации

OXIMES FOR TREATMENT OF PERIPHERAL AND CENTRAL NERVOUS SYSTEM EXPOSURE TO ACETYL CHOLINESTERASE INHIBITORS

Номер: US20140066421A1
Принадлежит: SOUTHWEST RESEARCH INSTITUTE

The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates. 2. The acetyl cholinesterase reactivator compound of wherein the reactivator is present as the E or Z isomer with respect to the oxime moiety.3. The acetyl cholinesterase reactivator compound of wherein said compound comprises a pharmaceutically acceptable salt comprising an acid addition salt or base addition salt.4. The acetyl cholinesterase reactivator compound of wherein said pharmaceutically acceptable salt comprises one or more of the following salts: acetate claim 3 , adipate claim 3 , aspartate claim 3 , benzoate claim 3 , besylate claim 3 , bicarbonate/carbonate claim 3 , bisulphate/sulphate claim 3 , borate claim 3 , citrate claim 3 , formate claim 3 , fumarate claim 3 , gluconate claim 3 , glucuronate claim 3 , hexafluorophosphate claim 3 , hydrochloride/chloride claim 3 , hydrobromide/bromide claim 3 , hydroiodide/iodide claim 3 , lactate claim 3 , malate claim 3 , maleate claim 3 , malonate claim 3 , mandelates claim 3 , mesylate claim 3 , methylsulphate claim 3 , naphthylate claim 3 , 2-napsylate claim 3 , nicotinate claim 3 , nitrate claim 3 , oxalate claim 3 , palmitate claim 3 , pamoate claim 3 , phosphate/hydrogen phosphate/dihydrogen phosphate claim 3 , pyroglutamate claim 3 , salicylate claim 3 , saccharate claim 3 , stearate claim 3 , succinate claim 3 , sulfonate claim 3 , stannate claim 3 , tartrate claim 3 , tosylate claim 3 , and trifluoroacetate salts.5. The acetyl cholinesterase reactivator compound of wherein said pharmaceutically acceptable salt comprises a base salt comprising one or more of the following: aluminium claim 3 , calcium claim 3 , choline claim 3 , diethylamine ...

Подробнее
06-03-2014 дата публикации

SERINE/THREONINE KINASE INHIBITORS

Номер: US20140066453A1
Принадлежит:

Compounds having the formula I wherein R, X and Z as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders. 2. The compound of wherein X is N.3. The compound of wherein X is CH.4. The compound of wherein Z is NH(CH)CHRAr and n is 1.5. The compound of wherein Z is NH(CH)CHRAr and n is 0.6. The compound of wherein Ris (a) hydrogen claim 1 , (b) Calkyl optionally substituted with one or more hydroxyl or Calkoxy groups claim 1 , (c) a pyrrolidinyl group optionally substituted by halogen claim 1 , or (d) a pyrazolyl or imidazolyl moiety optionally substituted with 1 to 3 Calkyl moieties claim 1 , and Ar is optionally substituted phenyl.7. The compound of wherein Ris (a) Calkyl claim 6 , (b) Calkyl substituted by a hydroxy group or (c) pyrazolyl optionally substituted by 1 or 2 Calkyl moieties.8. The compound of wherein Ris (a) (R)—Calkyl claim 7 , (b) (S) —Chydroxyalkyl or (c) (S)-1-Calkyl-1H-pyrazol-4-yl.9. The compound of wherein Ris (a) (R)-ethyl claim 8 , (b) (S)-2-hydroxymethyl or (c) (S)-1-methyl-1H-pyrazol-4-yl.10. The compound of wherein Ris (a) Chydroxyalkyl claim 1 , (b) heterocyclyl wherein said heterocycle is tetrahydropyranyl or tetrahydrofuranyl claim 1 , substituted by 1 to 3 groups independently selected from Calkyl claim 1 , halogen claim 1 , or Chydroxyalkyl or (c) heteroaryl wherein said heteroaryl is pyrazolyl claim 1 , N-alkyl-pyrazolyl or pyridinyl claim 1 , wherein the heteroaryl is optionally substituted by 1 to 3 Calkyl moieties.11. The compound of wherein Ris 1-methyl-1H-pyrazol-4-yl claim 10 , 2-methyl-2H-pyrazol-3-yl claim 10 , 2 claim 10 ,5-dimethyl-2H-pyrazol-3-yl claim 10 , tetrahydropyran-4-yl claim 10 , 3-fluoro-tetrahydropyran-4-yl claim 10 , tetrahydrofuran-3-yl or 2-hydroxy-1-methyl-ethyl.12. The compound of wherein Ar is phenyl optionally substituted by 1 or 2 groups independently selected from Calkoxy claim 1 , halogen claim 1 , Chaloalkoxy or cyano.13. The ...

Подробнее
06-03-2014 дата публикации

MODULATORS OF CELLULAR ADHESION

Номер: US20140066476A1
Принадлежит: SARcode Bioscience Inc.

The present invention provides compounds having formula (I): 175.-. (canceled)76. A pharmaceutical formulation comprising an LFA-1 antagonist or a pharmaceutically acceptable salt or ester thereof , and an excipient formulated for topical administration.80. The formulation of claim 76 , wherein the compound is present in an amount effective to modulate adhesion between intracellular adhesion molecules (e.g. claim 76 , ICAM-1 claim 76 , -2 and -3) and the leukocyte integrin family of receptors.81. The formulation of claim 76 , wherein the compound is present in an amount effective to antagonize CD11/CD18 receptors associated with leukocytes.82. The formulation of claim 76 , wherein the LFA-1 antagonist is a sodium claim 76 , potassium claim 76 , lithium claim 76 , magnesium claim 76 , or calcium salt.83. The formulation of claim 76 , wherein the formulation is in the form of an ointment claim 76 , paste claim 76 , cream claim 76 , lotion claim 76 , gel claim 76 , powder claim 76 , solution claim 76 , spray claim 76 , inhalant claim 76 , patch claim 76 , suspension claim 76 , emulsion claim 76 , crystalline form claim 76 , oil claim 76 , plaster claim 76 , liposome claim 76 , microemulsion claim 76 , or buffered solution.84. The formulation of claim 76 , wherein the excipient is selected from the group consisting of alcohols claim 76 , quaternary amines claim 76 , organic acids claim 76 , parabens claim 76 , phenols claim 76 , ascorbic acid claim 76 , ascorbic acid esters claim 76 , sodium bisulfite claim 76 , butylated hydroxytoluene claim 76 , butylated hydroxyanisole claim 76 , tocopherols claim 76 , chelating agents claim 76 , glycerine claim 76 , sorbitol claim 76 , polyethylene glycols claim 76 , urea claim 76 , propylene glycol claim 76 , citric buffer claim 76 , hydrochloric buffer claim 76 , lactic acid buffer claim 76 , quaternary ammonium chlorides claim 76 , cyclodextrins claim 76 , benzyl benzoate claim 76 , lecithin claim 76 , polysorbates claim 76 , ...

Подробнее
20-03-2014 дата публикации

AEROSOLIZED LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS

Номер: US20140079784A1
Автор: Burnier John, Gadek Thomas
Принадлежит: SARcode Bioscience Inc.

This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for aerosolized delivery. In particular, the LFA-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders using the LFA-1 aerosolized formulations of the present invention. 2. The formulation of claim 1 , wherein the LFA-1 antagonist achieves a local tissue concentration of greater than about 1 μM within about 30 min when administered to a subject.3. The formulation of claim 2 , wherein the local tissue concentration of the LFA-1 antagonist is maintained at a concentration of greater than about 10 nM for at least about 8 hours when administered to a subject.4. The formulation of wherein the LFA-1 antagonist is a directly competitive antagonist.5. (canceled)7. The formulation of wherein the LFA-1 antagonist is a sodium claim 6 , potassium claim 6 , lithium claim 6 , magnesium claim 6 , zinc claim 6 , or calcium salt.8. The formulation of claim 1 , wherein the LFA-1 antagonist inhibits T-cell attachment to ICAM-1 by about 50% or more at a concentration of about 100 nM.9. The formulation of claim 1 , wherein the propellant is a fluorocarbon claim 1 , alkane gas claim 1 , gaseous ether claim 1 , halide containing gas claim 1 , noble gas claim 1 , compressed air claim 1 , inert gas claim 1 , dry air claim 1 , normal air or foam.10. The formulation of claim 9 , wherein the fluorochlorocarbon is trichloro-monofluoromethane (F11) claim 9 , dichlorodifluoromethane (F12) claim 9 , monochlorotrifluoromethane (F13) claim 9 , dichloro-monofluoromethane (F21) claim 9 , monochlorodifluoromethane (F22) claim 9 , monochloromonofluoromethane (F31) claim 9 , 1 claim 9 ,1 claim 9 ,2-trichloro-1 claim 9 ,2 claim 9 ,2-trifluoroethane (F113) claim 9 , 1 claim 9 ,2-dichloro-1 claim 9 ,1 claim 9 ,2 claim 9 ,2- ...

Подробнее
20-03-2014 дата публикации

SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE

Номер: US20140080865A1
Принадлежит: SPINIFEX PHARMACEUTICALS PTY LTD

(S)-2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form is described together with its sodium salt and solvates. Methods for preparing the compound, its sodium salt and its solvates and pharmaceutical compositions comprising them are also described. 1. The sodium salt of (S)-2-(diphenylacetyl)-1 ,2 ,3 ,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid.2. The sodium salt according to in amorphous form.3. (S)-2-(Diphenylacetyl)-1 claim 1 ,2 claim 1 ,3 claim 1 ,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form.4. A pharmaceutical composition comprising the sodium salt of (S)-2-(diphenylacetyl)-1 claim 1 ,2 claim 1 ,3 claim 1 ,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid together with a pharmaceutically acceptable carrier claim 1 , diluent or excipient.5. The pharmaceutical composition of wherein the sodium salt of (S)-2-(diphenylacetyl)-1 claim 4 ,2 claim 4 ,3 claim 4 ,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid is in amorphous form.6. A pharmaceutical composition comprising (S)-2-(diphenylacetyl)-1 claim 4 ,2 claim 4 ,3 claim 4 ,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form together with a pharmaceutically acceptable carrier claim 4 , diluent or excipient.7. The pharmaceutical composition of formulated for oral delivery.8. The pharmaceutical composition of formulated for oral delivery.9. The pharmaceutical composition of formulated for oral delivery.10. The compound of wherein the enantiomeric purity is >97% ee.11. The compound of wherein the chemical purity is >96%.12. The compound of wherein said amorphous form exhibits a solid state C NMR spectrum comprising peaks at about 55.2 claim 2 , 109.8 claim 2 , 128.4 claim 2 , and 151.7 ppm.13. The compound of wherein said amorphous form exhibits a solid state C NMR spectrum ...

Подробнее
20-03-2014 дата публикации

Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors

Номер: US20140080866A1

Provided are tris-quaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse and/or gastrointestinal tract disorders. 119-. (canceled)21. The method of claim 20 , wherein the central nervous system associated disorder is selected from the group consisting of Alzheimer's disease claim 20 , dementia claim 20 , cognitive dysfunctions claim 20 , attention deficit disorders claim 20 , affective disorders claim 20 , extrapyramidal motor function disorders claim 20 , Parkinson's disease claim 20 , progressive supramolecular palsy claim 20 , Huntington's disease claim 20 , Gilles de la Tourette syndrome claim 20 , tardive dyskinesia claim 20 , neuroendocrine disorders claim 20 , dysregulation of food intake claim 20 , disorders of nociception claim 20 , pain claim 20 , mood and emotional disorders claim 20 , depression claim 20 , panic anxiety claim 20 , psychosis claim 20 , schizophrenia claim 20 , and epilepsy.22. The method of claim 20 , wherein the compound of Formula (I) binds selectively to one or more subtypes of the nicotinic acetylcholine receptors.23. The method of claim 22 , wherein administering the compound of Formula (I) activates the function of the nicotinic acetylcholine receptors as an agonist or as a partial agonist.24. The method of claim 22 , wherein administering the compound of Formula (I) inactivates the function of the nicotinic acetylcholine receptors as an antagonist.25. The method of claim 22 , wherein there is a decrease in the stimulant-evoked release of a neurotransmitter from a central nervous system tissue.26. The method of claim 22 , wherein there is an increase in the release of a neurotransmitter from a central nervous system tissue.27. The method of claim 25 , wherein the neurotransmitter is ...

Подробнее
27-03-2014 дата публикации

Novel antibacterial combination therapy

Номер: US20140088069A1
Принадлежит: Individual

An antibacterial composition is provided including a combination of a β-lactam antibiotic that has a binding affinity for bacterial penicillin-binding protein 2; and a non-antibiotic compound which may be a thienopyridine or a non-thienopyridine compound. A method of treatment using the composition is also provided.

Подробнее
27-03-2014 дата публикации

FLUORINATED ARYLALKYLAMINOCARBOXAMIDE DERIVATIVES

Номер: US20140088074A1
Автор: Pevarello Paolo
Принадлежит: NEWRON PHARMACEUTICALS S.P.A.

Fluorinated arylalkylaminocarboxamide derivatives of formula (I) are described wherein W, J, n, R, R, R, R, Rand Rhave the meanings as defined in the specification and pharmaceutically salts thereof, pharmaceutical compositions containing them as active ingredients and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urological, and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role. 2. A compound of claim 1 , wherein:{'sub': 2', 'm', '1', '4', '3', '6, 'W is a group A-[(CH)—O]— wherein: m is zero, 1, 2 or 3; A is (C-C)alkyl optionally substituted by one to three fluorine atoms; (C-C)cycloalkyl; phenyl optionally substituted with a halo group; or thiazolyl'}{'sub': 1', '4, 'J independently is hydrogen; C-Calkyl; chloro; or fluoro;'} [{'sup': '1', 'sub': 1', '4', '1', '4', '3', '6, 'Ris hydrogen; (C-C)alkyl optionally substituted with a hydroxy group or a (C-C)alkoxy group; or (C-C)cycloalkyl;'}, {'sup': '2', 'sub': 1', '4, 'Ris hydrogen; or (C-C)alkyl;'}, {'sup': '2′', 'sub': 1', '4', '1', '4', '1', '4, 'R is hydrogen or (C-C)alkyl optionally substituted with a (C-C)alkoxy or a phenyl group, the phenyl group being optionally substituted with a (C-C)alkoxy group;'}, {'sup': '3', 'sub': 1', '4, 'Ris hydrogen; or (C-C)alkyl;'}, {'sup': '4', 'sub': 1', '4, 'Ris hydrogen; (C-C)alkyl; phenyl; or cyclohexyl; or'}], 'n is 1 or 2;'}{'sup': 3', '4, 'sub': 1', '2', '1', '4, 'claim-text': [{'sup': '5', 'Ris hydrogen or fluoro; and'}, {'sup': '6', 'Ris fluoro;'}], 'Rand R, taken together with the adjacent nitrogen atom, form an azetidinyl, pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl, the piperydinyl ring being optionally substituted with one or two (C-C)alkyl group(s) and the piperazinyl ring being optionally substituted on the other N-atom with a (C-C)alkyl, ...

Подробнее
27-03-2014 дата публикации

SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF

Номер: US20140088076A1
Принадлежит: Genentech, Inc.

The invention provides novel compounds having the general formula: 3. The compound of claim 2 , wherein R claim 2 , Rand R claim 2 , if present claim 2 , are each independently selected from the group consisting of hydrogen claim 2 , Calkyl claim 2 , Chaloalkyl claim 2 , —CF claim 2 , —OCF claim 2 , —SF claim 2 , F claim 2 , Cl claim 2 , Br and I.4. The compound of claim 2 , wherein in R claim 2 , Xis absent or is selected from Calkylene and 3-6 membered cycloalkylene; and Ris selected from the group consisting of hydrogen claim 2 , Calkyl claim 2 , Chaloalkyl claim 2 , Cheteroalkyl claim 2 , Calkenyl claim 2 , Calkynyl claim 2 , 3-6 membered cycloalkyl claim 2 , 3-6 membered heterocycloalkyl claim 2 , 6-10 membered aryl claim 2 , and 5-10 membered heteroaryl claim 2 , wherein Xand Rare each independently optionally substituted.5. The compound of claim 4 , wherein in R claim 4 , Xis absent.6. The compound of claim 4 , wherein in R claim 4 , Ris selected from the group consisting of hydrogen claim 4 , Calkyl claim 4 , Chaloalkyl claim 4 , Cheteroalkyl claim 4 , Calkenyl and Calkynyl.7. The compound of claim 4 , wherein in R claim 4 , Ris optionally substituted with from 1 to 5 Rgroups selected from the group consisting of F claim 4 , Cl claim 4 , Br claim 4 , I claim 4 , OH claim 4 , NH claim 4 , SH claim 4 , CN claim 4 , NO claim 4 , Calkoxy claim 4 , Calkylamino and Cdialkylamino.8. The compound of claim 2 , wherein in R claim 2 , Ris selected from the group consisting of cycloprop-1-yl claim 2 , cyclobut-1-yl claim 2 , cyclopent-1-yl claim 2 , pyrimidin-2-yl claim 2 , pyrimidin-4-yl claim 2 , pyrimidin-5-yl claim 2 , pyridin-2-yl claim 2 , pyridin-4-yl claim 2 , pyridin-3-yl claim 2 , pyridin-2-on-6-yl claim 2 , pyridine-2-on-5-yl claim 2 , pyridine-2-on-4-yl claim 2 , pyridine-2-on-3-yl claim 2 , cyclohex-1-yl claim 2 , phenyl claim 2 , 4 claim 2 ,5-dihydrooxazol-2-yl claim 2 , oxazol-2-yl claim 2 , piperidin-4-yl claim 2 , piperidin-3-yl claim 2 , piperidin-2-yl ...

Подробнее
03-04-2014 дата публикации

Anti-fibrotic pyridinones

Номер: US20140094456A1
Принадлежит: Intermune Inc

Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.

Подробнее
03-04-2014 дата публикации

Compounds as S-Nitrosoglutathione Reductase Inhibitors

Номер: US20140094465A1
Принадлежит:

The present invention is directed to compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same. 1. What is claimed is: {'br': None, 'sub': 1', '2, 'HO-Cy-linker-Cy-acidic moiety\u2003\u2003Formula 1'}, 'A method of inhibiting GSNOR in a patient in need thereof by administering an effective amount of a compound of Formula 1 or a pharmaceutically acceptable salt thereofwherein{'sub': '1', 'Cyis selected from the group consisting of substituted and unsubstituted monocyclic aryl, substituted and unsubstituted bicyclic aryl, substituted and unsubstituted monocyclic heterocycle, substituted and unsubstituted bicyclic heterocycle, substituted and unsubstituted monocyclic heteroaryl, substituted and unsubstituted bicyclic heteroaryl, substituted and unsubstituted monocyclic cycloalkyl, and substituted and unsubstituted bicyclic cycloalkyl;'}{'sub': 2', '5', '6', '7', '2', '3', '2', '3', '2', '3', '5', '6', '1', '6', '1', '6', '1', '6', '7', '1', '6', '1', '6', '1', '6', '2', '3', '2', '3', '2', '3', '1', '3', '1', '3', '1', '3', '1', '8', '1', '8', '1', '8, 'linker is selected from the group consisting of a direct bond, O, S, SO, SO, C═O, CRR, NR, substituted and unsubstituted (C-C) alkyl, substituted and unsubstituted (C-C) heteroalkyl, substituted and unsubstituted (C-C) alkene, substituted and unsubstituted 5 or 6 membered aryl, substituted and unsubstituted 5 or 6 membered heteroaryl, substituted and unsubstituted 3-6 membered cycloalkyl, and substituted and unsubstituted 3-6 membered saturated heterocyclyl; wherein Rand Rare independently selected from the group consisting of hydrogen, (C-C) alkyl, (C-C) heteroalkyl, halogen, (C-C) haloalkyl, cyano, and hydroxyl; Ris selected from the group consisting of hydrogen, (C-C)alkyl, (C-C) haloalkyl, and (C-C) heteroalkyl; substitutions for the (C-C) alkyl, (C-C) heteroalkyl, and (C-C) alkene are selected from the group ...

Подробнее
10-04-2014 дата публикации

Guanidine compound

Номер: US20140100210A1
Принадлежит: Astellas Pharma Inc

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.

Подробнее
07-01-2021 дата публикации

METHODS FOR TREATING DEPRESSIVE SYMPTOMS

Номер: US20210000818A1
Принадлежит:

The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A. 16-. (canceled)9. (canceled)10. The method of claim 7 , wherein the compound is a μ opioid receptor agonist that exhibits an Emax of 5% to 45% in a GTPγS binding assay.11. The method of claim 10 , wherein the Emax is 15% to 35% in a GTPγS binding assay.12. The method of claim 10 , wherein said agonist has a low risk of opioid dependence claim 10 , opioid addiction claim 10 , and/or symptoms of opioid withdrawal.13. The method of claim 7 , wherein the compound exhibits a maximal dopamine efflux in the nucleus accumbens of 125% to 300% over base line in a rat.14. The method of claim 13 , wherein the compound has a maximal dopamine efflux in the nucleus accumbens of 200% to 300% over base line in a rat.15. The method of claim 7 , wherein the compound does not attenuate thermal pain in a rodent hot plate model when administered at a dose of at least 1 mg/kg.16. The method of claim 15 , wherein the compound does not attenuate thermal pain in a rodent hot plate model when administered at a dose of at least 3 mg/kg.17. The method of claim 15 , wherein the compound does not attenuate thermal pain in a rodent hot plate model when administered at a dose of 10 mg/kg.1825-. (canceled)26. The method of claim 7 , wherein the subject is a human.27. The method of claim 7 , wherein the depressive symptom is depressed mood claim 7 , loss of pleasure claim 7 , loss of appetite claim 7 , sleep disturbance claim 7 , psychomotor changes claim 7 , fatigue claim 7 , and/or post-partum depression.28. The method of claim 7 , wherein the depressive symptom is associated with a mental condition claim 7 , wherein the mental condition is ...

Подробнее
07-01-2021 дата публикации

USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES

Номер: US20210000846A1
Принадлежит:

The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2). 4. The method of claim 1 , wherein the local delivery is topical dermal delivery.5. The method of claim 2 , wherein the local delivery is topical dermal delivery.6. The method of claim 3 , wherein the local delivery is topical dermal delivery.7. The method of claim 4 , wherein the pharmaceutical composition is in a form selected from the group consisting of a cream claim 4 , a lotion claim 4 , a gel claim 4 , a solution claim 4 , a spray claim 4 , a foam claim 4 , a suspension and an emulsion.8. The method of claim 5 , wherein the pharmaceutical composition is in a form selected from the group consisting of a cream claim 5 , a lotion claim 5 , a gel claim 5 , a solution claim 5 , a spray claim 5 , a foam claim 5 , a suspension and an emulsion.9. The method of claim 6 , wherein the pharmaceutical composition is in a form selected from the group consisting of a cream claim 6 , a lotion claim 6 , a gel claim 6 , a solution claim 6 , a spray claim 6 , a foam claim 6 , a suspension and an emulsion. This application is a continuation of U.S. patent application Ser. No. 16/566,682, filed Sep. 10, 2019, which is a continuation of U.S. patent application Ser. No. 15/490,127, filed Apr. 18, 2017, now U.S. Pat. No. 10,434,112, which is a continuation of U.S. patent application Ser. No. 14/196,155, filed Mar. 4, 2014, now abandoned, which claims the benefit of U.S. Provisional Patent Application Ser. No. 61/773,778 filed Mar. 6, 2013, which are herein incorporated by reference in their entireties and serve as the basis of a priority and/or benefit claim for the present application.The present invention relates to a method for treating dermal ...

Подробнее
02-01-2020 дата публикации

BENZOQUINOLONE INHIBITORS OF VMAT2

Номер: US20200000794A1
Принадлежит:

The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof. 2. The long acting pharmaceutical formulation of claim 1 , comprising the salt of the compound.3. The long acting pharmaceutical formulation of claim 1 , wherein each position represented as D has deuterium enrichment of no less than about 50%.4. The long acting pharmaceutical formulation of claim 1 , wherein each position represented as D has deuterium enrichment of no less than about 90%.5. The long acting pharmaceutical formulation of claim 1 , wherein each position represented as D has deuterium enrichment of no less than about 98%.6. The long acting pharmaceutical formulation of claim 1 , wherein the depot preparation is in the form of an emulsion.7. The long acting pharmaceutical formulation of claim 1 , comprising from 5 mg to 500 mg of the compound.8. A method of treating a VMAT2-mediated disorder in a patient in need of treatment comprising administering to the patient a long acting pharmaceutical formulation of .9. The method of claim 8 , wherein the disorder is a chronic hyperkinetic movement disorder claim 8 , Huntington's disease claim 8 , hemiballismus claim 8 , senile chorea claim 8 , a tic disorder claim 8 , tardive dyskinesia claim 8 , dystonia claim 8 , Tourette's syndrome claim 8 , depression claim 8 , cancer claim 8 , rheumatoid arthritis claim 8 , psychosis claim 8 , multiple sclerosis claim 8 , or asthma.10. The method of claim 9 , wherein the disorder is a chronic hyperkinetic movement disorder.11. The method of claim 10 , wherein the chronic hyperkinetic movement disorder is Huntington's disease.12. The method of claim 10 , wherein the chronic hyperkinetic movement disorder is tardive dyskinesia.13. The method of claim 10 , wherein the chronic hyperkinetic movement disorder is Tourette's syndrome.14. The method of claim 8 , wherein the administration is via implantation.15. The method of claim 14 , wherein ...

Подробнее
03-01-2019 дата публикации

TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF

Номер: US20190000832A1
Принадлежит: Selder Pharma Inc.

To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS. 17-. (canceled)9. The pharmaceutical composition of claim 8 , wherein Ris —N(R)-lower alkylene-(aryl or heteroaryl claim 8 , which may each be substituted) claim 8 , or —N(R)—O-lower alkylene-(aryl or heteroaryl claim 8 , which may each be substituted).10. The pharmaceutical composition of claim 9 , wherein Ris phenyl which may be substituted with halogen claim 9 , lower alkyl claim 9 , or —OR.11. The pharmaceutical composition of claim 9 , wherein Ris —H.12. The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition is a solid composition.13. The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition is a liquid composition.14. The pharmaceutical composition of claim 13 , wherein the liquid composition is for parenteral administration.15. The pharmaceutical composition of claim 13 , wherein the liquid composition is for oral administration.17. The compound of claim 16 , wherein Ris —N(R)-lower alkylene-(aryl or heteroaryl claim 16 , which may each be substituted) claim 16 , or —N(R)—O-lower alkylene-(aryl or heteroaryl claim 16 , which may each be substituted).18. The compound of claim 17 , wherein Ris (lower alkylene)-OH or substituted cycloalkyl claim 17 , wherein said lower alkylene may be substituted with a member selected from the group consisting of —OH and phenyl (which may be substituted ...

Подробнее
03-01-2019 дата публикации

PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS

Номер: US20190000845A1
Принадлежит:

This invention is directed to a compound of formula (I): 224-. (canceled) The present invention is directed to phenyloxadiazole compounds, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of the prostaglandin D synthase.Allergic rhinitis, the most common atopic disease, has an estimated prevalence ranging from about 5 to about 22 percent of the general human population and is characterized by the symptoms of sneezing, nasal discharge, and nasal congestion. These symptoms are believed to be triggered by multiple mediators released from mast cells and other inflammatory cells. Current therapies, such as antihistamines, deal effectively with the sneezing and nasal discharge, but have little effect on congestion, which is a key symptom affecting the quality of life of patients.Local allergen challenge in patients with allergic rhinitis, bronchial asthma, allergic conjunctivitis and atopic dermatitis has been shown to result in rapid elevation of prostaglandin D2 “(PGD2)” levels in nasal and bronchial lavage fluids, tears and skin chamber fluids. PGD2 has many inflammatory actions, such as increasing vascular permeability in the conjunctiva and skin, increasing nasal airway resistance, airway narrowing and cosinophil infiltration into the conjunctiva and trachea. PGD2 is the major cyclooxygenase product of arachidonic acid produced from mast cells on immunological challenge [Lewis, R A, Soter N A, Diamond P T, Austen K F, Oates J A, Roberts L J II, Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE, 129, 1627-1631, 1982]. Activated mast cells, a major source of PGD2, are one of the key players in driving the allergic response in conditions such as asthma, allergic rhinitis, allergic conjunctivitis, allergic dermatitis and other diseases [Brightling C E, Bradding P, Pavord I D, Wardlaw A J, New Insights ...

Подробнее
07-01-2016 дата публикации

HETEROCYCLIC COMPOUND

Номер: US20160002169A1
Принадлежит:

The present invention provides a heterocyclic compound having a RORγt inhibitory action. 4. The compound or salt of claim 1 , wherein Ris a group represented by the formula: —C(R)(CH)(CH) wherein Ris bonded to one substituent on Ring A to form an optionally substituted 5-membered hydrocarbon ring claim 1 , wherein the one substituent on Ring A is bonded to the position adjacent to the bonding position of Ron Ring A.5. The compound or salt of claim 1 , wherein Ris cyclopropyl or cyclobutyl claim 1 , each optionally substituted.6. The compound or salt of claim 1 , wherein{'sup': 1', '1a', '1a', '1, 'sub': 3', '3, 'Ris a group represented by the formula: —C(R)(CH)(CH) wherein Ris bonded to one substituent on Ring A to form an optionally substituted 5-membered hydrocarbon ring, wherein the one substituent on Ring A is bonded to the position adjacent to the bonding position of Ron Ring A;'}{'sup': '4', 'Ris cyclopropyl or cyclobutyl, each optionally substituted; and'}Ring D is not formed.7. ((1R claim 1 ,2S)-2-(((5R)-5-((7-Fluoro-1 claim 1 ,1-dimethyl-2 claim 1 ,3-dihydro-1H-inden-5-yl)carbamoyl)-2-methoxy-7 claim 1 ,8-dihydro-1 claim 1 ,6-naphthyridin-6(5H)-yl)carbonyl)cyclopropyl)acetic acid or a salt thereof.8. cis-3-(((5R)-5-((7-Fluoro-1 claim 1 , l-dimethyl-2 claim 1 ,3-dihydro-1H-inden-5-yl)carbamoyl)-2-methoxy-7 claim 1 ,8-dihydro-1 claim 1 ,6-naphthyridin-6(5H)-yl)carbonyl)cyclobutanecarboxylic acid or a salt thereof.9. (cis-3-(((5R)-5-((7-Fluoro-1 claim 1 ,1-dimethyl-2 claim 1 ,3-dihydro-1H-inden-5-yl)carbamoyl)-2-methoxy-7 claim 1 ,8-dihydro-1 claim 1 ,6-naphthyridin-6(5H)-yl)carbonyl)cyclobutyl)acetic acid or a salt thereof.10. (cis-3-(((1R)-1-((7-Fluoro-1 claim 1 ,1-dimethyl-2 claim 1 ,3-dihydro-1H-inden-5-yl)carbamoyl)-6-(methoxymethyl)-3 claim 1 ,4-dihydroisoquinolin-2(1H)-yl)carbonyl)cyclobutyl)acetic acid or a salt thereof.11. A medicament comprising the compound or salt of .12. The medicament of claim 11 , which is a RORγt inhibitor.13. The medicament of ...

Подробнее
07-01-2016 дата публикации

CRYSTALLINE FORMS OF -ACETIC ACID

Номер: US20160002170A1
Принадлежит:

The present disclosure relates to crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid (Compound A), the process of preparing crystalline forms of Compound A, the pharmaceutical compositions containing them, and the methods of use thereof. 3. Compound A claim 2 , Form 1 of claim 2 , characterized by having an X-ray powder diffractogram comprising at least one peak selected from 7.7 claim 2 , 11.2 claim 2 , 13.8 claim 2 , 14.7 claim 2 , 15.3 claim 2 , 15.8 claim 2 , 18.3 claim 2 , 21.1 claim 2 , and 22.2°2θ±0.2°2θ claim 2 , as determined on a diffractogram using Cu—Kα radiation.4. Compound A claim 3 , Form 1 of claim 3 , wherein the diffractogram comprises a peak at 18.3°2θ±0.2°2θ.5. Compound A claim 4 , Form 1 of claim 4 , wherein the diffractogram further comprises a peak at 11.2±0.2°2θ.6. Compound A claim 5 , Form 1 of claim 5 , wherein the diffractogram further comprises peaks at 7.7 claim 5 , 13.8 claim 5 , 21.1 and 22.2°2θ±0.2°2θ.7. Compound A claim 6 , Form 1 of claim 6 , wherein the diffractogram is substantially as shown in .8. Compound A claim 2 , Form 1 of claim 2 , characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 251° C.9. Compound A claim 8 , Form 1 of claim 8 , further comprising an exotherm at about 210° C.10. Compound A claim 9 , Form 1 of claim 9 , wherein the DSC curve is substantially as shown in .11. Compound A claim 2 , Form 1 of claim 2 , characterized by a diffractogram which is substantially as shown in claim 2 , and by a DSC curve which is substantially as shown in .13. Compound A claim 12 , Form 2 of claim 12 , characterized by having an X-ray powder diffractogram comprising at least one peak selected from 8.1 claim 12 , 10.6 claim 12 , 11.5 claim 12 , 14.5 claim 12 , 16.2 claim 12 , 19.3 claim 12 , 21.5 claim 12 , 21.9 claim 12 , 22.7 claim 12 , 24.5 claim 12 , and 26.6°2θ±0.2°2θ claim 12 , as determined on a diffractogram using Cu—Kα ...

Подробнее